10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________________________

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2013

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number: 001-33718

________________________

BIOHEART, INC.
(Exact name of registrant as specified in its charter)

________________________

Florida	65-0945967
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

13794 NW 4^th Street, Suite 212, Sunrise, Florida 33325
(Address of principal executive offices) (Zip Code)

(954) 835-1500
(Registrant’s telephone number, including area code)

______________
 
Securities registered under Section 12(b) of the Exchange Act:

None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, $0.001 par value per share

(Title of Class)

_____________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x   No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.045 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o   No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨	Smaller reporting company x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨   No  x.

As of April 30, 2013, there were 200,623,903 outstanding shares of the registrant’s common stock, par value $0.001 per share.

Transitional Small Business Disclosure Format Yes  o    No  x

BIOHEART, INC. AND SUBSIDIARIES

INDEX TO FORM 10-Q FILING

MARCH 31, 2013

TABLE OF CONTENTS

PART I		Financial Information	Page Number
	Item 1.	Financial Information	3
		Condensed Consolidated Balance Sheets – March 31, 2013 (Unaudited) and December 31, 2012	4
		Unaudited Condensed Consolidated Statements of Operations (Unaudited) – Three Months Ended March 31, 2013, March 31, 2012 and the period from August 12, 1999 (date of inception) to March 31, 2013	5
		Unaudited Condensed Consolidated Statements of Stockholders Deficit (Unaudited) –Three Months Ended March 31, 2013	6
		Unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) – Three Months Ended March 31, 2013, March 31, 2012 and the period from August 12, 1999 (date of inception) to March 31, 2013	7
		Notes to Unaudited Condensed Consolidated Financial Statements	9
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	29
	Item 4.	Controls and Procedures	30
PART II		Other Information	31
	Item 1.	Legal Proceedings	31
	Item 1A.	Risk Factors	31
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	31
	Item 3.	Defaults Upon Senior Securities	31
	Item 4.	Mine Safety Disclosures	31
	Item 5.	Other Information	32
	Item 6.	Exhibits	32
SIGNATURES			36
EX-31.1		Management certification	37
EX-32.1		Sarbanes-Oxley Act	38
EX-32.2		Sarbanes-Oxley Act	39
EX-10.87		2013 Omnibus Equity Compensation Plan	40

2

PART I – FINANCIAL INFORMATION

Item 1.

Interim Financial Statements and Notes to Interim Financial Statements

General

The accompanying interim financial statements have been prepared in accordance with the instructions to Form 10-Q. Therefore, they do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' equity in conformity with generally accepted accounting principles. Except as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements included in the Company's annual report on Form 10-K for the year ended December 31, 2012. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Operating results for the three months ended March 31, 2013 are not necessarily indicative of the results that can be expected for the year ending December 31, 2013.

3

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
CONDENSED CONSOLIDATED BALANCE SHEETS
		March 31,			December 31,
		2013			2012
		(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	239,033		$	—
Accounts receivable, net		1,704			1,342
Inventory		—			62,953
Prepaid and other		79,360			41,533
Total current assets		320,097			105,828
Property and equipment, net		1,050			1,820
Other assets		54,661			54,662
Total assets	$	375,808		$	162,310
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Bank overdraft	$	—		$	89
Accounts payable		2,533,718			2,618,567
Accrued expenses		4,820,969			5,364,017
Advances, related party		1,047,992			867,492
Deposits		465,286			465,286
Subordinated debt, related party		1,500,000			1,500,000
Notes payable, related party		966,227			966,227
Notes payable, net of debt discount		1,989,810			2,364,972
Total current liabilities		13,324,002			14,146,650
Long term debt:
Derivative liability		1,069,190			611,227
Stockholders'  deficit:
Preferred stock, par value $0.001; 20,000,000 and 5,000,000 shares authorized as of March 31, 2013 and December 31, 2012, respectively,  -0-  issued and outstanding as of March 31, 2013 and December 31, 2012		—			—
Common stock, par value $0.001; 950,000,000 and 195,000,000 shares authorized as of March 31, 2013 and December 31, 2012, respectively, 190,496,693 and 182,062,802 shares issued and outstanding as of March 31, 2013 and December 31, 2012, respectively		190,497			182,063
Additional paid in capital		100,948,736			100,260,094
Common stock subscription		400,000			—
Deficit accumulated during development stage		(115,556,617	)		(115,037,724	)
Total stockholders' deficit		(14,017,384	)		(14,595,567	)
Total liabilities and stockholders' deficit	$	375,808		$	162,310
See the accompanying notes to these unaudited condensed consolidated financial statements

4

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
							From August 12,
							1999 (date of
							Inception) to
	Three months ended March 31,						March 31, 2013
	2013			2012			(Unaudited)
Revenue	$	4,192		$	40,485		$	1,273,832
Cost of sales		—			417			551,904
Gross profit		4,192			40,068			721,928
Operating expenses:
Research and development		163,974			96,729			64,857,026
Marketing, general and administrative		370,533			468,099			37,208,369
Impairment of investment		—			—			58,695
Depreciation and amortization		769			4,325			898,683
Total operating expenses		535,276			569,153			103,022,773
Net loss from operations		(531,084	)		(529,085	)		(102,300,845	)
Other income (expenses):
Development revenues		—			—			117,500
Net gain on settlement of debt and trade payables		1,004,224			—			1,004,224
Loss on change of fair value of derivative liability		(640,589	)		—			(545,820	)
Interest income		—			—			762,277
Other income		939			11,353			272,004
Interest expense		(352,383	)		(429,160	)		(14,865,957	)
Total other income (expenses)		12,191			(417,807	)		(13,255,772	)
Net loss before income taxes		(518,893	)		(946,892	)		(115,556,617	)
Income taxes (benefit)		—			—			—
NET LOSS	$	(518,893	)	$	(946,892	)	$	(115,556,617	)
Net loss per common share, basic and diluted	$	(0.003	)	$	(0.008	)
Weighted average number of common shares outstanding, basic and diluted		185,421,093			114,974,051
See the accompanying notes to these unaudited condensed consolidated financial statements

5

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT
THREE MONTHS ENDED MARCH 31, 2013
(Unaudited)
													Deficit
													Accumulated
									Additional		Common		During
	Preferred stock				Common stock				Paid in		Stock		Development
	Shares		Amount			Shares	Amount		Capital		Subscribed		Stage				Total
Balance, December 31, 2012		—	$	—		182,062,802	$	182,063	$	100,260,094	$	—	$	(115,037,724	)	$	(14,595,567	)
Reclassify  the fair value of excess committed shares liability to equity upon common share authorization increase		—		—		—		—		474,954		—		—			474,954
Common stock issued in connection with issuance of convertible debt		—		—		2,500,000		2,500		33,750		—		—			36,250
Common stock issued in connection with settlement of debt		—		—		1,000,000		1,000		18,500		—		—			19,500
Common stock issued in settlement of accounts payable		—		—		4,933,891		4,934		141,807		—		—			146,740
Proceeds from common stock subscription		—		—		—		—		—		400,000		—			400,000
Stock based compensation		—		—		—		—		19,632		—		—			19,632
Net loss		—		—		—		—		—		—		(518,893	)		(518,893	)
Balance, March 31, 2013		—	$	—		190,496,693	$	190,497	$	100,948,736	$	400,000	$	(115,556,617	)	$	(14,017,384	)
See the accompanying notes to these unaudited condensed consolidated financial statements

6

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
							From August 12,
							1999 (date of
	Three months ended March 31,						Inception) to
	2013			2012			March 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(518,893	)	$	(946,892	)	$	(115,556,617	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		769			4,325			898,684
Bad debt expense		—			—			166,266
Discount on convertible debt		124,838			248,776			1,736,406
Loss on change in fair value of derivative liability		640,589			—			545,820
Net gain on settlement of debt and trade payables		(1,004,224	)		—			(1,004,224	)
Non cash payment of interest		123,578			21,169			394,688
Amortization of warrants issued in exchange for licenses and intellectual property		—			—			5,413,156
Amortization of warrants issued in connection with notes payable		—			50,761			5,437,604
Amortization of loan costs		—			927			1,228,717
Warrants issued in exchange for services		—			—			285,659
Warrants issued in exchange for forbearance agreement		—			—			430,213
Equity instruments issued in connection with R&D agreement		—			—			360,032
Equity instruments issued in connection with settlement agreement		—			—			3,381,629
Common stock issued in connection with accounts payable		—			—			756,816
Common stock issued in exchange for services		—			10,000			1,482,522
Common stock issued in connection with amounts due to guarantors of Bank of America loan		—			—			69,159
Common stock issued in exchange for distribution rights and intellectual property		—			—			99,997
Warrants issued in connection with accounts payable					—			7,758
Stock based compensation		19,632			19,051			9,970,634
(Increase) decrease in:
Receivables		(362	)		3,495			(2,969	)
Inventory		62,953			416			(1	)
Prepaid and other current assets		(37,827	)		(38,599	)		(89,329	)
Other assets		1			—			(28,854	)
Increase (decrease) in:
Accounts payable		(12,509	)		254,157			3,247,170
Accrued expenses		55,077			288,031			6,793,321
Deferred revenue		—			—			465,287
Net cash used in operating activities		(546,378	)		(84,383	)		(73,510,456	)

7

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
						From August 12,
						1999 (date of
	Three months ended March 31,					Inception) to
	2013			2012		March 31, 2013
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisitions of property and equipment		—			—		(899,733	)
Net cash used by investing activities		—			—		(899,733	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Bank overdraft		(89	)		—		—
Proceeds from issuance of common stock, net		400,000			117,500		64,281,775
Proceeds from (payments for) initial public offering of common stock, net		—			—		1,447,829
Proceeds from subordinated related party note		—			—		3,000,000
Payment of note payable		—			—		(3,000,000	)
Proceeds from notes payable, related party		—			—		505,000
Proceeds from related party advances		180,500			—		1,047,992
Proceeds from exercise of stock options		—			—		293,749
Proceeds from notes payable		205,000			—		11,825,750
Repayments of notes payable		—			—		(3,533,605	)
Payment of loan costs		—			—		(1,219,268	)
Net cash provided in financing activities		785,411			117,500		74,649,222
Net (decrease) increase in cash and cash equivalents		239,033			33,117		239,033
Cash and cash equivalents, beginning of period		—			36,828		—
Cash and cash equivalents, end of period	$	239,033		$	69,945	$	239,033
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	$	103,969		$	128,696	$	2,288,051
Income taxes paid	$	—		$	—	$	—
Non cash financing activities:
Common stock issued in settlement of notes payable	$	19,500		$	387,033	$	4,252,959
Common stock issued in settlement of accounts payable	$	146,740		$	—	$	160,740
See the accompanying notes to these unaudited condensed consolidated financial statements

8

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2013

NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES

A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed consolidated financial statements follows:

General

The accompanying unaudited condensed consolidated financial statements of Bioheart, Inc., (the “Company”), have been prepared in accordance with the rules and regulations (S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three month period ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ended December 31, 2013. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated December 31, 2012 financial statements and footnotes thereto included in the Company’s SEC Form 10-K.

Basis and business presentation

Bioheart, Inc (the “Company”) was incorporated under the laws of the State of Florida in August 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through March 31, 2013, the Company has accumulated a deficit through its development stage of $115,556,617.

The unaudited condensed consolidated financial statements include the accounts of the Company, and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Comprehensive Income

The Company does not have any items of comprehensive income in any of the periods presented.

Net Loss per Common Share, basic and diluted

The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options and warrants have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 222,688,816 and 124,077,413 for the three months ended March 31, 2013 and 2012, respectively.

9

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2013

Stock based compensation

The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values. (See note 10).

As of March 31, 2013, there were outstanding stock options to purchase 7,817,852 shares of common stock, 3,681,284 shares of which were vested.

Concentrations of Credit Risk

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. The financial stability of these institutions is periodically reviewed by senior management.

As of March 31, 2013 and December 31, 2012, two (2) and one (1) customer represented 100% and 96% of the Company’s accounts receivable, respectively.

For the three month periods ended March 31, 2013 and 2012, the Company's revenues earned from the sale of products and services were $4,192 and $40,895, from two (2) and two (2) customers, respectively.

Reliance on Key Personnel and Consultants

The Company has 3 full-time employees and 1  part-time employee. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.

Research and Development

The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $163,974 and $96,729 for the three months ended March 31, 2013 and 2012, respectively; and $64,857,026 from August 12, 1999 (date of inception) to March 31, 2013.

Fair Value

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

10

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2013

The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.

Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2013 and December 31, 2012, the Company did not have any derivative instruments that were designated as hedges.

Recent Accounting Pronouncements

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed consolidated financial position, results of operations or cash flows.

NOTE 2 – GOING CONCERN MATTERS

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed consolidated financial statements, during three months ended March 31, 2013, the Company incurred net losses attributable to common shareholders of $518,893 and used $546,378 in cash for operating activities. As of March 31, 2013, the Company   had a working capital deficit of approximately $13.0 million. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.

The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

NOTE 3 – INVENTORY

Inventory consists of raw materials. Costs of raw materials are determined using the FIFO method. Inventory is stated at the lower of costs or market (estimated net realizable value). During the quarter ended March 31, 2013, the Company recorded a reserve for obsolescence of the full balance of inventory.

NOTE 4 – PROPERTY AND EQUIPMENT

Property and equipment as of March 31, 2013 and December 31, 2012 is summarized as follows:

11

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2013

	March 31, 2013			December 31, 2012
Laboratory and medical equipment	$	352,358		$	352,358
Furniture, fixtures and equipment		130,916			130,916
Computer equipment		54,414			54,414
Leasehold improvements		362,046			362,046
		899,734			899,734
Less accumulated depreciation and amortization		(898,684	)		(897,914	)
	$	1,050		$	1,820

Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives.

Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment.

NOTE 5 – ACCRUED EXPENSES

Accrued expenses consisted of the following as of March 31, 2013 and December 31, 2012:

	March 31, 2013		December 31, 2012
License and royalty fees	$	1,898,453	$	1,825,675
Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest		1,314,795		1,284,705
Interest payable on notes payable		507,644		1,100,174
Vendor accruals and other		174,268		120,133
Employee commissions, compensation, etc.		925,809		1,033,330
	$	4,820,969	$	5,364,017

During the three months ended March 31, 2013, 1,000,000 shares of restricted common stock were issued to one debt holder  in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note.

NOTE 6 – STANDBY EQUITY DISTRIBUTION AGREEMENT

On November 2, 2011, the Company and Greystone Capital Partners (“Greystone”) entered into a Standby Equity Distribution Agreement (the “Agreement”).  Pursuant to the Agreement, Greystone has agreed to provide the Company with up to $1,000,000 of funding for the 24-month period following the date a registration statement of the Company’s common stock is declared effective by the SEC (the “Equity Line”).  During this 24-month period, commencing on the date on which the SEC first declares effective our registration statement, the Company may request a draw down under the Equity Line by which the Company would sell shares of its common stock to Greystone, which is obligated to purchase the shares under the Agreement.  

For each share of our common stock purchased under the Agreement, Greystone will pay eighty percent (80%) of the average of the lowest daily volume weighted average price for five consecutive trading days immediately preceding Advance Notice (the "Valuation Period") commencing the date an Advance Notice (the "Advance Notice") is delivered to Greystone in a manner provided by the Agreement. Subject to certain limitations and floor price reductions, the Company may, at its sole discretion, issue a Put Notice to Greystone and Greystone will then

12

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2013

be irrevocably bound to acquire such shares. The registration statement relating to the requested bond of the Company's common stock pursuant to the Agreement was declared effective on February 10, 2012.

NOTE 7 – NOTES PAYABLE

Notes payable were comprised of the following as of March 31, 2013 and December 31, 2012:

	March 31, 2013				December 31, 2012
Seaside Bank note payable.	$	980,000		$	980,000
August 2008 Unsecured Promissory Note		500,000			1,000,000
Hunton & Williams notes payable		384,972			384,972
IBC Funds note payable		125,000			—
Asher notes payable		80,000			—
Total notes payable		2,069,972			2,364,972
Less unamortized debt discount		(80,162	)		—
Total notes payable net of unamortized debt discount	$	1,989,810		$	2,364,972

Seaside Bank

On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by shareholders of the Company.

August 2008 Unsecured Promissory Note

On August 20, 2008, the Company borrowed $1.0 million from a third party pursuant to the terms of an unsecured Promissory Note and Agreement. Outstanding principal and interest on the loan, which accrues at the rate of 13.5% per annum, is payable in one balloon payment upon the Company’s repayment of the BlueCrest Loan, which is scheduled to mature in May 2010, however the Company is not obligated to make payments until BlueCrest Loan is paid off. In the event the Company completes a private placement of its common stock and/or securities exercisable for or convertible into its common stock which generates at least $19.0 million of gross proceeds, the Company may prepay, without penalty, all outstanding principal and interest due under the loan using the same type of securities issued in the subject private placement. Because repayment of the loan could occur within 12 months from the date of the balance sheet, the Company has classified this loan as short term. Subject to certain conditions, at the end of each calendar quarter during the time the loan is outstanding, the Company may, but is not required to, pay all or any portion of the interest accrued but unpaid as of such date with shares of its common stock. In April 2009, as consideration for the authorization to amend certain documents related to the Note, the Company issued to the Noteholder a warrant to purchase 451,053 shares of common stock at an exercise price of $0.5321 per share.

The warrant, which became exercisable immediately upon issuance, has a ten year term. This warrant had a fair value of $195,694, which was accounted for as additional paid in capital and reflected as a component of debt discount and is being amortized as interest expense ratably over the term of the loan.

During the three months ended March 31, 2013, 1,000,000 shares of restricted common stock were issued to the debt holder,  in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note resulting in a gain of $1,078,625. A gain of $1,078,625 was included in the net gain on settlement of debt and trade payables on the statement of operations.

Hunton & Williams Notes

At March 31, 2013 and December 31, 2012, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822 are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.

13

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2013

IBC Funds, LLC Note

On January 9, 2013, the Company issued an unsecured promissory note and 2,500,000 shares of common stock with IBC Funds LLC. (“IBC”) in the principal amount of $125,000 (the “Note”).

The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on April 15, 2013. The Note is convertible into common stock, at IBC’s option, at a 60% discount to the average of the three lowest closing prices of the common stock during the 5 trading day period prior to conversion. The Company has identified the embedded derivatives related to the IBC Note. These embedded derivatives included certain conversion features provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of IBC Note and to fair value as of each subsequent reporting date. At the inception of the IBC Note, the Company determined the aggregate fair value of $198,987 of the embedded derivatives.

The fair value of the embedded derivatives was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 155.34%, (3) weighted average risk-free interest rate of 0.06%, (4) expected life of 0.26 year, and (5) estimated fair value of the Company’s common stock of $0.0135 per share. The initial fair value of the embedded debt derivative of $198,987 was allocated as a debt discount up to the proceeds of the note ($125,000) with the remainder ($73,987) charged to current period operations as interest expense. For three months ended March 31, 2013, the Company amortized $105,469 of debt discount to current period operations as interest expense.

Asher Notes (During this quarter)

During the three months ended March 31, 2013, the Company entered into a Securities Purchase Agreements with Asher Enterprises, Inc. (“Asher”), for the sale of an 8% convertible notes in aggregate principal amount of $80,000 (the “Note”).

The Notes bear interest at the rate of 8% per annum. All interest and principal must be repaid between September 11, 2013 and November 22, 2013. The Notes are convertible into common stock, at Asher’s option, at a 42% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes. These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Note and to fair value as of each subsequent reporting date. At the inception of the Asher Notes, the Company determined the aggregate fair value of $93,342 of the embedded derivatives.

The fair value of the embedded derivatives was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 154.80% to 155.34%, (3) weighted average risk-free interest rate of 0.09% to 0.17%, (4) expected lives of 0.67 to .75 years, and (5) estimated fair value of the Company’s common stock from $0.0151 to $0.0373 per share. The initial fair value of the embedded debt derivative of $93,342 was allocated as a debt discount up to the proceeds of the note ($80,000) with the remainder ($13,342) charged to current period operations as interest expense. For the three months ended March 31, 2013, the Company amortized $19,369 of debt discount to current period operations as interest expense.

NOTE 8 — RELATED PARTY TRANSACTIONS

Lease Guarantee

The Company’s former Chairman of the Board, Chief Executive Officer and Chief Technology Officer has personally guaranteed the Company’s obligations under its lease for its facilities in Sunrise, Florida and has provided a personal guarantee for the Company credit card, which is for his own use only.

14

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2013

Advances

As of March 31, 2013 and December 31, 2012, the Company officers and directors have provided advances in the aggregate of $1,047,992 and $867,492 respectively, for working capital purposes. The advances are unsecured, due on demand and non-interest bearing.

Notes payable-related party

Northstar Biotechnology Group, LLC

On February 29, 2012, the Note issued to BlueCrest Master Fund Limited (as described above) was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267.

On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. As of September 30, 2012, the Company was in default, however, subsequent to September 30, 2012, the Company renegotiated the terms of the note, Northstar has agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in restricted stock.

On September 21, 2012, the company issued 5,000,000 warrants to Northstar that was treated as Additional interest expense upon issuance.

On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement whereby the Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights. As of March 31, 2013 the principle of this note was $601,227. In addition to the above consideration of preferred and common stock, the company issued 15,000,000 million warrants pursuant to the agreement.

In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.

Effective October 1, 2012, the effective interest rate will be 12.85% per annum.

In connection with the consideration paid, Northstar shall waive, from the effective date through the earlier of termination or expiration of the agreement, or satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued. In addition, the Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012).

Officer and Director Notes

At March 31, 2013 and December 31, 2012, the Company has outstanding notes payable to officers and directors with interest at 8% per annum due at maturity. The three subordinated notes, $125,000, $100,000 and $140,000 were previously due on October 22, 2012, November 30, 2012 and June 4, 2011 respectively, and are unsecured. The company is not obligated to make payment until Northstar loan is paid off.

Subordinated debt, related party

As of March 31, 2013 and December 31, 2012, the Company officers and directors have provided notes in aggregate of $1,500,000. The notes are at 8% per annum and are due upon payoff of the Northstar note payable described above.

15

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2013

NOTE 9 — DERIVATIVE LIABILITIES

Excessive committed shares

On December 31, 2012, in connection with the previously issued stock options and warrants, the Company had the possibility of exceeding their common shares authorized when considering the number of possible shares that may be issuable to satisfy settlement provisions of these agreements after consideration of all existing instruments that could be settled in shares. The accounting treatment of derivative financial instruments required that the Company reclassify the derivative from equity to a liability at their fair values as of the date possible issuable shares exceeded the authorized level and at fair value as of each subsequent balance sheet date. Any change in fair value was recorded as non-operating, non-cash income or expense at each reporting date. If the fair value of the derivatives was higher at the subsequent balance sheet date, the Company recorded a non-operating, non-cash charge. If the fair value of the derivatives was lower at the subsequent balance sheet date, the Company recorded non-operating, non-cash income.

On February 4, 2013, in conjunction with the increase in authorized number of shares to 970,000,000, the Company determined it had adequate authorized shares to settle all of these agreements. As such, the Company adjusted the derivative liability to fair value on February 4, 2013 and reclassified the derivative liability to equity. The fair value of the derivative liability of $474,954 (a non-cash item) as of February 4, 2013 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 156.52%; risk free rate: 0.38%; and expected life: 3.5 years. The Company recorded a loss on change in derivative liabilities of $84,907 during the three months ended March 31, 2013.

Reset warrants

On October 1, 2012, in connection with the forbearance agreement with Northstar as discussed in Note 8 above, the Company issued an aggregate of 15,000,000 warrants to purchase the Company’s common stock with an exercise price of $0.014 per share for ten years with anti-dilutive (reset) provisions.

The Company has identified embedded derivatives related to the issued warrants. These embedded derivatives included certain and anti-dilutive (reset) provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to fair value as of each subsequent reporting date.

At March 31, 2013, the fair value of the reset provision of $566,806 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 168.90%; risk free rate: 1.87%; and expected life: 9.50 years. The Company recorded a loss on change in derivative liabilities of $345,627 during the three months ended March 31, 2013.

16

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2013

Convertible notes

During the three months ended March 31, 2013, the Company issued convertible notes (see Note 7 above).

These notes are convertible into common stock, at holders’ option, at a discount to the market price of the Company’s common stock. The Company has identified the embedded derivatives related to these notes. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Note and to fair value as of each subsequent reporting date.

The fair value of the embedded derivatives at March 31, 2013, in the amount of $502,384, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 168.90%, (3) weighted average risk-free interest rate of 0.119% to 0.17%, (4) expected lives of 0.04 to 0.65 years, and (5) estimated fair value of the Company’s common stock of $0.038 per share. The Company recorded a loss on change in derivative liabilities of $210,056 during the three months ended March 31, 2013.

Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

At March 31, 2013, the aggregate derivative liabilities was valued at $1,069,190, the Company believes an event under the contract that would create an obligation to settle in cash or other current assets is remote and has classified the obligation as a long term liability.

NOTE 10 – STOCKHOLDERS’ EQUITY

Preferred stock

On August 17, 2012, the board of directors designated 5,000,000 shares of preferred stock as Series A Convertible Preferred Stock which was increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. Each share of preferred stock is convertible into equal number of common shares at the option of the holder; entitled to 10 votes on all matters presented to be voted by the holders of common stock; upon event of liquidation, entitled to amount equal to stated value plus any accrued and unpaid dividends or other fees before distribution to junior securities.

Common stock

On February 4, 2013, the Company amended its Articles of Incorporation to increase the number of authorized shares to 970,000,000, consisting of 20,000,000 $0.001 par value preferred stock and 950,000,000 $0.001 common stock.

During the three months ended March 31, 2013, the Company issued an aggregate of 4,933,891 share of its common stock for settlement of $72,339 of accounts payable. In connection with the settlement, the Company recorded a loss on settlement of debt of $74,401.

During the three months ended March 31, 2013, the Company issued 2,500,000 shares of its common stock in connection with the issuance of a note payable.

During the three months ended March 31, 2013, the Company issued 1,000,000 shares of its common stock in connection with the settlement of a note payable.

17

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2013

NOTE 11 — STOCK OPTIONS AND WARRANTS

Stock Options

In December 1999, our Board of Directors and shareholders adopted our 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011.

In April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty million shares for issuance.

Effective April 1, 2013, the BOD resolved that stock options granted for the past three years as of February 25, 2013 be repriced for employees, management and board members, at the exercise price of the average of the last 5 trading days’ closing price as of February 25, 2013.

A summary of options at March 31, 2013 and activity during the year then ended is presented below:

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)
Options outstanding at January 1, 2012		4,636,318		$	1.20		8.1
Granted		3,300,000		$	0.04
Exercised				$
Forfeited/Expired		(82,942	)	$	5.57
Options outstanding at December 31, 2012		7,853,376		$	0.67		8.2
Granted				$
Exercised
Forfeited/Expired		(35,524	)	$	5.67
Options outstanding at March 31, 2013		7,817,852		$	0.64		8.0
Options exercisable at March 31, 2013		3,681,284		$	1.28
Available for grant at March 31, 2013		0

The following information applies to options outstanding and exercisable at March 31, 2013:

	Options Outstanding							Options Exercisable
	Shares		Weighted- Average Remaining Contractual Term		Weighted- Average Exercise Price		Shares			Weighted- Average Exercise Price
$0.00 – $0.70		6,794,360		8.7	$	0.12			2,599,127		$	0.18
$0.71 – $1.28		324,471		5.1	$	0.77			392,136		$	0.76
$5.25 – $5.67		652,653		2.6	$	5.56			643,653		$	5.57
$7.69		39,572		3.4	$	7.69			39,572		$	7.69
$8.47		6,796		4.0	$	8.47			6,796		$	8.47
		7,817,852		8.0	$	0.64			3,681,284		$	1.28

18

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2013

The fair value of all options vesting during the three months ended March 31, 2013 and 2012 of $19,632 and $19,051, respectively, was charged to current period operations.

Warrants

A summary of warrants at March 31, 2013 and activity during the year then ended is presented below:

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)
Outstanding at January 1, 2012		32,610,075		$	0.86		3.8
Issued		42,396,432		$	0.018		5.78
Exercised		—		$	0.00
Forfeited		(933,185	)	$	0.69
Outstanding at December 31, 2012		74,073,322		$	0.37		4.5
Issued		23,421,250		$	0.018		3.74
Exercised		—		$
Expired		(1,675,614	)	$	0.73
Outstanding at March 31, 2013		95,818,958		$	0.28		4.2
Exercisable at March 31, 2013		70,853,258		$	0.21		4.2

In conjunction with the authorized issuance of common stock, the Company granted approximately 23 million warrants during the quarter ended March 31, 2013.

The following information applies to warrants outstanding and exercisable at March 31, 2013:

	Warrants Outstanding						Warrants Exercisable
	Shares		Weighted- Average Remaining Contractual Term		Weighted- Average Exercise Price		Shares		Weighted- Average Exercise Price
$0.01 – $0.50		89,044,402		4.0	$	0.04		65,623,152		$	0.04
$0.52 – $0.68		2,831,642		5.8	$	0.58		2,831,642		$	0.58
$0.70 – $1.62		1,096,632		5.2	$	0.73		1,096,632		$	0.73
$3.60 – $4.93		105,000		0.4	$	4.87		105,000		$	4.87
$5.67 – $7.69		2,741,282		9.5	$	7.52		1,196,832		$	7.31
		95,818,958		4.2	$	0.28		70,853,258		$	0.21

NOTE 12 — COMMITMENTS AND CONTINGENCIES

Royalty Payments

The Company is obligated to pay royalties on commercial sales of certain products that may be developed and sold under various licenses and agreements that have been obtained by the Company.

19

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2013

The Company has entered into various licensing agreements, which include the potential for royalty payments, as follows:

William Beaumont Hospital

In June 2000, the Company entered into an exclusive license agreement to use certain patents for the life of the patents in future projects. The patents expire in 2015. In addition to a payment of $55,000 the Company made to acquire the license, the Company is required to pay an annual license fee of $10,000 and royalties ranging from 2% to 4% of net sales of products that are covered by the patents. In order to maintain the exclusive license rights, the agreement also calls for a minimum annual royalty threshold. The minimum royalty threshold was $200,000 for 2011 and $200,000 for 2010. This minimum royalty threshold will remain $200,000 for 2012 and thereafter. As of March 31, 2013, the Company has not made any payments other than the initial payment to acquire the license. At March 31, 2013 and December 31, 2012, the Company’s liability under this agreement was $1,898,453 and $1,825,675, respectively, which is reflected as a component of accrued expenses on the consolidated balance sheets (see Note 5). During the three months ended March 31, 2013 and 2012, the Company incurred expenses of $72,778, $52,500, and $1,898,453 from August 12, 1999 (date of inception) to March 31, 2012. The Company has accrued interest for the past due commitment at 2% over the prime rate per the terms of the agreement. The Company has included $335,953 in accrued expenses as of March 31, 2013.

Approximate annual future minimum obligations under this agreement as of March 31, 2013 are as follows:

Year Ending December 31,
2013	$	157,500
2014		210,000
2015		210,000
Total	$	577,500

Contingency for Registration of the Company’s common stock

The Company believes that it may have issued options to purchase common stock to certain of its employees, directors and consultants in California in violation of the registration or qualification provisions of applicable California securities laws. As a result, the Company intends to make a rescission offer to these persons. The Company will make this offer to all persons who have a continuing right to rescission, which it believes to include two persons. In the rescission offer, in accordance with California law, the Company will offer to repurchase all unexercised options issued to these persons at 77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted. Based upon the number of options that were subject to rescission as of December 31, 2009, assuming that all such options are tendered in the rescission offer, the Company estimated that its total rescission liability would be up to approximately $371,000. However, as the Company believes there is only a remote likelihood the rescission offer will be accepted by any of these persons in an amount that would result in a material expenditure by the Company, no liability was recorded as of March 31, 2013 or December 31, 2012.

Litigation

The Company is subject to other legal proceedings that arise in the ordinary course of business. In the opinion of management, as of March 31, 2013, the amount of ultimate liability with respect to such matters, if any, in excess of applicable insurance coverage, is not likely to have a material impact on the Company’s business, financial position, consolidated results of operations or liquidity. However, as the outcome of litigation and other claims is difficult to predict significant changes in the estimated exposures could exist.

20

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2013

NOTE 13 — FAIR VALUE MEASUREMENT

The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the consolidated financial statements.

The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.

As of March 31, 2013 or December 31, 2012, the Company did not have any items that would be classified as level 1 or 2 disclosure.

The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in note 9 above. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

March 31, 2013 and December 31, 2012, the Company did not have any derivative instruments that were designated as hedges.

21

BIOHEART, INC. AND SUBSIDIARIES
(a development stage company)
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2013

The derivative liability as of March 31, 2013, in the amount of $1,069,190 has a level 3 classification.

The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of March 31, 2013:

	Derivative Liability
Balance, December 31, 2012	$	611,227
Total (gains) losses
Initial fair value of debt derivative at note issuance		292,328
Mark-to-market at March 31, 2013:		640,589
Transfers out of Level 3 upon increase in authorized shares		(474,954	)
Balance, March 31, 2013	$	1,069,190
Net Gain for the period included in earnings relating to the liabilities held at March 31, 2013	$	(640,589	)

NOTE 14 — SUBSEQUENT EVENTS

As of April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty million shares for issuance.

Effective April 1, 2013, the BOD resolved that stock options granted for the past three years as of February 25, 2013 be repriced for employees, management and board members, at the exercise price of the average of the last 5 trading days’ closing price as of February 25, 2013.  

As of April, 2013, the Company amended its facility lease to extend the term of the lease until July 31, 2013.

As of April 17, 2013, in regards to the forbearance agreement, the Company issued 10,000,000 shares of its common stock to Northstar Biotech Group, LLC.

As of April 25, 2013, in regards to the forbearance agreement and in lieu of interest payments owed through April 1, 2013, the Company issued 20,000,000 shares of its preferred stock to Northstar Biotech Group, LLC.

22

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations

Unless otherwise indicated, references in this Quarterly Report on Form 10-Q to “we,” “us,” and “our” are to the Company and all subsidiaries, unless the context requires otherwise. The following discussion and analysis by our management of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated interim financial statements and the accompanying related notes included in this quarterly report and our audited consolidated financial statements and related notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission.

Cautionary Statement Regarding Forward-Looking Statements

This report may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we intend that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Any such forward-looking statements would be contained principally in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors.” Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities and the effects of regulation. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss many of these risks in greater detail in “Risk Factors.” Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this report. You should read this report and the documents that we reference in this report and have filed as exhibits to the report completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Additional information concerning these and other risks and uncertainties is contained in our filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2012.

In this Quarterly Report on Form 10-Q, “Company,” “our company,” “us,” and “our” refer to Bioheart, Inc.,  unless the context requires otherwise.

Our Ability  to Continue as a Going Concern

Our independent registered public accounting firm has issued its report dated March 28, 2013, in connection with the audit of our consolidated financial statements as of December 31, 2012, that included an explanatory paragraph describing the existence of conditions that raise substantial doubt about our ability to continue as a going concern.

Our unaudited condensed consolidated financial statements as of March 31, 2013 have been prepared under the assumption that we will continue as a going concern. Specifically, Note 2 of our unaudited financial statement for the quarter ended March 31, 2013 addresses the issue of our ability to continue as a going concern. If we are not able to continue as a going concern, it is likely that holders of our common stock will lose all of their investment. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.

23

Overview

We are committed to maintaining our leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Our goals are to regenerate damaged tissue, if possible, improve a patient’s quality of life, reduce hospitalizations and reduce overall health care costs.

We were incorporated in the State of Florida in August 1999. Our principal executive offices are located at 13794 NW 4th Street, Suite 212, Sunrise, Florida 33325 and our telephone number is (954) 835-1500. Information about us is available on our corporate web site at www.bioheartinc.com. Information contained on the web site does not constitute part of, and is not incorporated by reference in, this report.

In January 2013, the Company amended its facility lease to extend the term of the lease until April 30, 2013.

In April 2013, the Company amended its facility lease to extend the term of the lease until July 31, 2013.

Biotechnology Product Candidates

Specific to biotechnology, we are focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. In our pipeline, we have multiple product candidates for the treatment of heart damage, including MyoCell, Myocell SDF-1, and Lipicell. MyoCell and MyoCell SDF-1 are clinical muscle-derived cell therapies designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

 MyoCell SDF-1 is intended to be an improvement to MyoCell. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector so that they will release extra quantities of the SDF-1 protein, which expresses angiogenic factors. LipiCell is a patient-derived cell therapy proposed for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. We hope to demonstrate that these product candidates are safe and effective complements to existing therapies for chronic and acute heart damage.

Our most recent completed clinical trials of MyoCell are the SEISMIC Trial, a 40-patient, randomized, multicenter, controlled, Phase II-a study conducted in Europe and the MYOHEART Trial, a 20-patient, multicenter, Phase I dose-escalation trial conducted in the United States. We were approved by the U.S. Food and Drug Administration, or the “FDA”, to proceed with a 330-patient, multicenter Phase II/III trial of MyoCell in North America and Europe, or the MARVEL Trial. We completed the MyoCell implantation procedure on the first patient in the MARVEL Trial on October 24, 2007. Thus far, 20 patients, including 6 control patients, have been treated. Initial results for the 20 patients were released at the Heart Failure Society of American meeting in September, 2009, showing a significant (35%) improvement in the 6 minute walk for those patients who were treated, and no improvement for those who received a placebo. On the basis of these results, we have applied for and received approval from the FDA to reduce the number of additional patients in the trial to 134, for a total of 154 patients. The SEISMIC, MYOHEART and MARVEL Trials have been designed to test the safety and efficacy of MyoCell in treating patients with severe, chronic damage to the heart. Upon regulatory approval of MyoCell, we intend to generate revenue in the United States from the sale of MyoCell cell-culturing services for treatment of patients by qualified physicians.

We received approval from the FDA in July of 2009 to conduct a Phase I safety study on 15 patients of a combined therapy (Myocell with SDF-1), which we believe was the first approval of a study combining gene and cell therapies. We initially commenced work on this study, called the REGEN Trial, during the first quarter of 2010. We suspended activity on the trial in 2010 while seeking additional funding necessary to conduct the trial.

We are seeking to secure sufficient funds to reinitiate enrollment in the MARVEL and REGEN trials. If we successfully secure such funds, we intend to re-engage a contract research organization, or CRO, investigators and certain suppliers to advance such trials.

24

MyoCell

MyoCell is a clinical therapy intended to improve cardiac function for those with congestive heart failure and is designed to be utilized months or even years after a patient has suffered severe heart damage due to a heart attack or other cause. We believe that MyoCell has the potential to become a leading treatment for severe, chronic damage to the heart due to its perceived ability to satisfy, at least in part, what we believe to be an unmet demand for more effective and/or more affordable therapies for chronic heart damage. MyoCell uses myoblasts, cells that are precursors to muscle cells, from the patient’s own body. The myoblasts are removed from a patient’s thigh muscle, isolated, grown through our proprietary cell culturing process, and injected directly in the scar tissue of a patient’s heart. A qualified physician performs this minimally invasive procedure using an endoventricular catheter. We entered into an agreement with a Johnson & Johnson company to use its NOGA® Cardiac Navigation System along with its MyoStar™ injection catheter for the delivery of MyoCell in the MARVEL Trial.

When injected into scar tissue within the heart wall, myoblasts have been shown to be capable of engrafting in the damaged tissue and differentiating into mature skeletal muscle cells. In a number of clinical and animal studies, the engrafted skeletal muscle cells have been shown to express various proteins that are important components of contractile function. By using myoblasts obtained from a patient’s own body, we believe MyoCell is able to avoid certain challenges currently faced by other types of cell-based clinical therapies including tissue rejection and instances of the cells differentiating into cells other than muscle. Although a number of therapies have proven to improve the cardiac function of a damaged heart, no currently available treatment, to our knowledge, has demonstrated an ability to generate new muscle tissue within the scarred regions of a heart.

Our completed clinical trials of MyoCell to date, including the SEISMIC Trial and the MYOHEART Trial have been primarily targeted to patients with severe, chronic damage to the heart who are in Class II or Class III heart failure according to the New York Heart Association, or NYHA, heart failure classification system. The NYHA system classifies patients in one of four categories based on how limited they are during physical activity. NYHA Class II heart failure patients have a mild limitation of activity and are generally comfortable at rest or with mild exertion while NYHA Class III heart failure patients suffer from a marked limitation of activity and are generally comfortable only at rest.

In addition to studies we have sponsored, we understand that myoblast-based clinical therapies have been the subject of at least eleven clinical trials involving more than 325 enrollees, including at least 235 treated patients. Although we believe many of the trials are different from the trials sponsored by us in a number of important respects, it is our view that the trials have advanced the cell therapy industry’s understanding of the potential opportunities and limitations of myoblast-based therapies.

We believe the market for treating patients in NYHA Class II or NYHA Class III heart failure is significant. According to the AHA Statistics and the European Society of Cardiology Task Force for the Treatment of Chronic Heart Failure, in the United States and Europe there are approximately 5.2 million and 9.6 million, respectively, patients with heart failure. The AHA Statistics further indicate that, after heart failure is diagnosed, the one-year mortality rate is high, with one in five dying and that 80% of men and 70% of women under age 65 who have heart failure will die within eight years. We believe that approximately 60% of heart failure patients are in either NYHA Class II or NYHA Class III heart failure based upon a 1999 study entitled “Congestive Heart Failure Due to Diastolic or Systolic Dysfunction – Frequency and Patient Characteristics in an Ambulatory Setting” by Diller, PM, et. al.

MyoCath Product Candidate

The MyoCath is a deflecting tip needle injection catheter that has a larger (25 gauge) needle to allow for better flow rates and less leakage than systems that are 27 gauge. This larger needle allows for thicker compositions to be injected, which helps with cell retention in the heart. Also, the MyoCath needle has more fluoroscopic brightness than the normally used nitinol needle, enabling superior visualization during the procedure. Seeing the needle well during injections enables the physician who is operating the catheter to pinpoint targeted areas more precisely. The MyoCath is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. Investigators in our MARVEL Trial may use either our MyoCath catheters or Biosense Webster’s (a Johnson & Johnson company) NOGA® Cardiac Navigation System along with the MyoStar injection catheter for the delivery of MyoCell to patients enrolled in the trial.

25

Vitalmex

On August 1, 2012, our Chief Executive Officer, in an open letter to shareholders, discussed active negotiations with several groups interested in helping us restart our FDA-approved clinical trials, including a non-binding term sheet and investment offer from Grupo Vitalmex in Mexico. Vitalmex’s operations include marketing and distributing specialized healthcare products, devices and therapies worldwide. While there can be no assurances that a definitive agreement will be reached, as of the date of this report, negotiations with Vitalmex are ongoing.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. While our critical accounting policies are described in Note 1 to our consolidated financial statements appearing elsewhere in this report, we believe the following policies are important to understanding and evaluating our reported financial results:

Stock-Based Compensation

The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values.       

Revenue Recognition

We recognize revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.

At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. If a significant portion of a fee is due after our normal payment terms or upon implementation or client acceptance, the fee is accounted for as not being fixed or determinable and revenue is recognized as the fees become due or after implementation or client acceptance has occurred. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client.

We account for Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets.

Unbilled revenue is revenue that is recognized but is not currently billable to the customer pursuant to contractual terms. In general, such amounts become billable in accordance with predetermined payment schedules, but recognized as revenue as services are performed. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets.

26

Research and Development Activities

We account for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred.

Derivative financial instruments

Accounting Standards Codification subtopic 815-40, Derivatives and Hedging, Contracts in Entity’s own Equity (“ASC 815-40”) became effective for the Company on October 1, 2009. The Company has identified the embedded derivatives related to the our issued Notes and anti-dilutive warrants.  These embedded derivatives included in our debt contain certain conversion features and reset provision.  The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Notes and to fair value as of each subsequent reporting date.  

Results of Operations

We are a development stage company and our MyoCell product candidate has not received regulatory approval or generated any material revenues and is not expected for a year or two, if ever. We have generated substantial net losses and negative cash flow from operations since inception and anticipate incurring significant net losses and negative cash flows from operations for the foreseeable future as we continue clinical trials, undertake new clinical trials, apply for regulatory approvals, make capital expenditures, add information systems and personnel, make payments pursuant to our license agreements upon our achievement of certain milestones, continue development of additional product candidates using our technology, establish sales and marketing capabilities and incur the additional cost of operating as a public company.

Comparison of the Three Months Ended March 31, 2013 and 2012

Revenues

We recognized revenues of $4,192 in the three month period ended March 31, 2013 compared to revenues of $40,485 in the three month period ended March 31, 2012. The revenue in the three month period ended March 31, 2013 was generated from laboratory services.

Cost of Sales

Cost of sales was $0 in the three month period ended March 31, 2013 compared to $417 in the three month period ended March 31, 2012.

Research and Development

Research and development expenses were $163,974 in the three month period ended in March 31, 2013, an increase of $67,245 from the research and development expenses of $96,729 in the three month period ended in March 31, 2012. The increase was primarily attributable to an increase in the amount of funds allocated to our clinical trials.

The timing and amount of our planned research and development expenditures is dependent on our ability to obtain additional financing. See “- Existing Capital Resources and Future Capital Requirements” and Item 1A. “Risk Factors - We will need to secure additional financing …” as filed with our Form 10-K with the Securities and Exchange Commission on April 12, 2012.

27

Marketing, General and Administrative

Marketing, general and administrative expenses were approximately $370,533 in the three month period ended March 31, 2013, a decrease of $97,566 from marketing, general and administrative expenses of approximately $468,099 in the three month period ended in March 31, 2012. The decrease in marketing, general and administrative expenses is attributable, in part, to lower compensation to officers, directors and key employees.

Gain on settlement of debt

During the three months ended March 31, 2013, we settled an outstanding note payable and certain accounts payable by issuances of common stock. As such we realized a net $1,004,224 gain on settlement of debt during the three months ended March 31, 2013, as compared to nil for same period last year.

Loss on change in fair value of derivative liabilities.

As of March 31, 2013, we issued convertible notes and warrants with anti-dilutive provisions that had the possibility of exceeding our common shares authorized when considering the number of possible shares that may be issuable to satisfy settlement provisions of these agreements after consideration of all existing instruments that could be settled in shares. As such, we are required to determine the fair value of this derivative and mark to market each reporting period. For the three months ended March 31, 2013, we incurred a $640,589 loss on change in fair value of our derivative liabilities compared to nil the same period last year.

 Interest Expense

Interest expense was $352,383 in the three month period ended March 31, 2013 compared to interest expense of $429,160 in the three month period ended in March 31, 2012, a decrease of $76,777. During the three months ended March 31, 2013, we incurred a non-cash interest expense of $248,416 from the set up and amortization of debt discounts associated with our issued convertible notes as compared to $320,706 for the same period last year.

Inflation

Our opinion is that inflation has not had, and is not expected to have, a material effect on our operations.

Climate Change

Our opinion is that neither climate change, nor governmental regulations related to climate change, have had, or are expected to have, any material effect on our operations.

Concentrations of Credit Risk

As of March 31, 2013 and December 31, 2012, two (2) and two (2) customers represented 100% and 98% of the Company’s accounts receivable, respectively.

Liquidity and Capital Resources

In the three months ended March 31, 2013, we continued to finance our considerable operational cash needs with cash generated from financing activities.

Operating Activities

Net cash used in operating activities was $546,378 in the three month period ended March 31, 2013 as compared to $84,383 of cash used in the three month period ended in March 31, 2013.

28

Our use of cash for operations in the three months ended March 31, 2013 reflected a net loss generated during the period of approximately $0.5 million, adjusted for non-cash items such as stock-based compensation of $19,632, depreciation of $770, amortization of debt discounts of $124,838, loss on change in fair value of derivative liabilities of $640,589 and non-cash interest paid of $123,578, net with gain on settlement of debt of $1,004,224. In addition we had a net decrease in operating assets of $24,764 and an increase in accrued expenses of $55,077 and a decrease in accounts payable of $12,509.

Our use of cash for operations in the three months ended March 31, 2012 reflected a net loss generated during the period of approximately $0.9 million, adjusted for non-cash items such as stock-based compensation of $19,051, amortization of the fair value of warrants granted in connection with the Note payable of $50,761, amortization of debt discounts incurred in connection with the BlueCrest Loan and Bank of America and other Loans of $248,776, non-cash interest paid of $21,169 and depreciation of $4,325. In addition we had a net increase in operating assets of $34,688 and an increase in accrued expenses of $288,031 and in accounts payable of $254,157.

Investing Activities

Net cash used in investing activities was nil for the three months ended March 31, 2013 and 2012.

Financing Activities

Net cash provided by financing activities was an aggregate of $785,411 in the three month period ended March 31, 2013 as compared to $117,500 in the three month period ended in March 31, 2012. In the three month period ended March 31, 2013 we sold, in private placements, shares of common stock and warrants for aggregate net cash proceeds of $400,000, received proceeds from issuance of note payable of $205,000 and related party advances of $180,500.

Existing Capital Resources and Future Capital Requirements

Our MyoCell product candidate has not received regulatory approval or generated any material revenues. We do not expect to generate any material revenues or cash from sales of our MyoCell product candidate until commercialization of MyoCell, if ever. We have generated substantial net losses and negative cash flow from operations since inception and anticipate incurring significant net losses and negative cash flows from operations for the foreseeable future. Historically, we have relied on proceeds from the sale of our common stock and our incurrence of debt to provide the funds necessary to conduct our research and development activities and to meet our other cash needs.

At March 31, 2013, we had cash and cash equivalents totaling $239,033 however, our working capital deficit as of such date was approximately $13.0 million. Our independent registered public accounting firm has issued its report dated March 28, 2013 in connection with the audit of our consolidated financial statements as of December 31, 2012 that included an explanatory paragraph describing the existence of conditions that raise substantial doubt about our ability to continue as a going concern and Note 2 of our unaudited financial statement for the quarter ended March 31, 2013 addresses the issue of our ability to continue as a going concern

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required under Regulation S-K for “smaller reporting companies.”

29

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our CEO and Chief Accounting Officer, as appropriate, to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our CEO and Principal Financial and Accounting Officer, an evaluation was performed on the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on that evaluation, our management, including our CEO and Principal Financial and Accounting Officer, concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report due to the Company’s limited resources and limited number of employees. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of legal and outsourced accounting professionals. As we grow, we expect to increase our number of employees, which, we believe, will enable us to implement adequate segregation of duties within the internal control framework.

Changes In Internal Control Over Financial Reporting

There were no changes in the Company’s internal controls over financial reporting during the most recently completed fiscal quarter that have materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.

30

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

Our Company is not involved in any material litigation and we are unaware of any threatened material litigation. However, the biotechnology and medical device industries have been characterized by extensive litigation regarding patents and other intellectual property rights. In addition, from time to time, we may become involved in litigation relating to claims arising from the ordinary course of our business.

Item 1A. Risk Factors

Not required under Regulation S-K for “smaller reporting companies.”

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Subscription Agreements  – Common Stock and Warrants

In March  2013, the Company sold an aggregate of 22,988,724 shares of the Company’s common stock and common stock purchase warrants to purchase 23,421,250 shares of the Company’s common stock for aggregate gross cash proceeds of $400,000. The warrants are (i) exercisable solely for cash at an exercise price of $0.01734 to $0.0184 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time during the period commencing on the date that is six months and one day following the date of issuance and ending on the tenth year anniversary of the date of issuance.

During the three months ended March 31, 2013, 1,000,000 shares of restricted common stock were issued to one debt holder  in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note.

In April, 2013, the Company sold an aggregate of 6,057,181 shares of the Company’s common stock and common stock purchase warrants to purchase 6,057,181 shares of the Company’s common stock for aggregate gross cash proceeds of $135,000. The warrants are (i) exercisable solely for cash at an exercise price of $0.0173 to $0.0381 per share, (ii) non-transferable for six months following issuance and (iii) exercisable, in whole or in part, at any time during the period commencing on the date that is six months and one day following the date of issuance and ending on the tenth year anniversary of the date of issuance.

The offer and sale of such shares of our common stock and warrants were effected in reliance on the exemptions for sales of securities not involving a public offering, as set forth in Rule 506 promulgated under the Securities Act of 1933 (the “Securities Act”) and in Section 4(2) of the Securities Act, based on the following: (a) the investors confirmed to us that they were “accredited investors,” as defined in Rule 501 of Regulation D promulgated under the Securities Act and had such background, education and experience in financial and business matters as to be able to evaluate the merits and risks of an investment in the securities; (b) there was no public offering or general solicitation with respect to the offering; (c) the investors were provided with certain disclosure materials and all other information requested with respect to our company; (d) the investors acknowledged that all securities being purchased were “restricted securities” for purposes of the Securities Act, and agreed to transfer such securities only in a transaction registered under the Securities Act or exempt from registration under the Securities Act; and (e) a legend was placed on the certificates representing each such security stating that it was restricted and could only be transferred if subsequent registered under the Securities Act or transferred in a transaction exempt from registration under the Securities Act.

Item 3. Defaults Upon Senior Securities

There were no defaults upon senior securities during the period ended March 31, 2013.

Item 4. Mine Safety Disclosures

Not applicable. 

31

Item 5. Other Information

There is no information with respect to which information is not otherwise called for by this form.

Item 6. Exhibits

Exhibit No.	Exhibit Description
3.1(6)	Amended and Restated Articles of Incorporation of the registrant, as amended
3.2(9)	Articles of Amendment to the Articles of Incorporation of the registrant
3.3(8)	Amended and Restated Bylaws
4.1(5)	Loan and Security Agreement, dated as of May 31, 2007 by and between BlueCrest Capital Finance, L.P. and the registrant
4.2(12)	Notice of Event of Default, from BlueCrest Venture Finance Master Fund Limited to the Company, dated January 28, 2009
4.3(12)	Notice of Acceleration, from BlueCrest Venture Finance Master Fund Limited to the Company, dated February 2, 2009
4.4(13)	Amendment to Loan and Security Agreement, between the Company and BlueCrest Venture Finance Master Fund Limited, dated as of April 2, 2009
4.5(13)	Grant of Security Interest (Patents), between the Company and BlueCrest Venture Finance Master Fund Limited, dated as of April 2, 2009
4.6(13)	Security Agreement (Intellectual Property), between the Company and BlueCrest Venture Finance Master Fund Limited, dated as of April 2, 2009
4.7(13)	Subordination Agreement, by Hunton & Williams, LLP in favor of BlueCrest Venture Finance Master Fund Limited, entered into and effective April 2, 2009
4.8(13)	Amended and Restated Promissory Note, dated April 2, 2009, by the Company to BlueCrest Venture Finance Master Fund Limited
4.9(13)	Warrant to purchase 1,315,542 shares of the registrant’s common stock, dated April 2, 2009, issued to BlueCrest Venture Finance Master Fund Limited
4.10(14)	Warrant to purchase 451,043 shares of the registrant’s common stock, dated April 2, 2009, issued to Rogers Telecommunications Limited
4.11(14)	Warrant to purchase 173,638 shares of the registrant’s common stock, dated April 2, 2009, issued to Hunton & Williams, LLP
4.12(4)	Warrant to purchase shares of the registrant's common stock issued to Howard J. Leonhardt and Brenda Leonhardt
4.12(19)	10% Convertible Promissory Note Due July 23, 2010, in the amount of $20,000, payable to Dana Smith
4.13(19)	10% Convertible Promissory Note Due July 23, 2010, in the amount of $100,000, payable to Bruce Meyers
4.14(19)	Registration Rights Agreement, dated July 23, 2009
4.15(4)	Warrant to purchase shares of the registrant's common stock issued to the R&A Spencer Family Limited Partnership
4.15(19)	Subordination Agreement, dated July 23, 2009
4.16(19)	Note Purchase Agreement, dated July 23, 2009
4.17(19)	Closing Confirmation of Conversion Election, dated July 23, 2009
4.20(6)	Warrant to purchase shares of the registrant's common stock issued to Samuel S. Ahn, M.D.
4.23(7)	Warrant to purchase shares of the registrant's common stock issued to Howard and Brenda Leonhardt
4.27(11)	Form of Warrant Agreement for October 2008 Private Placement
4.30(19)	10% Convertible Promissory Note Due July 23, 2010, in the amount of $100,000, payable to Bruce Meyers
10.1**(1)	1999 Officers and Employees Stock Option Plan
10.2**(1)	1999 Directors and Consultants Stock Option Plan
10.3(1)	Form of Option Agreement under 1999 Officers and Employees Stock Option Plan
10.4(3)	Form of Option Agreement under 1999 Directors and Consultants Stock Option Plan
10.5**(4)	Employment Letter Agreement between the registrant and Scott Bromley, dated August 24, 2006.
10.6(1)	Lease Agreement between the registrant and Sawgrass Business Plaza, LLC, as amended, dated November 14, 2006.

32

10.7(1)	Asset Purchase Agreement between the registrant and Advanced Cardiovascular Systems, Inc., dated June 24, 2003.
10.8(4)	Conditionally Exclusive License Agreement between the registrant, Dr. Peter Law and Cell Transplants International, LLC, dated February 7, 2000, as amended.
10.9(4)	Loan Guarantee, Payment and Security Agreement, dated as of June 1, 2007, by and between the registrant, Howard J. Leonhardt and Brenda Leonhardt
10.10(4)	Loan Guarantee, Payment and Security Agreement, dated as of June 1, 2007, by and between the registrant and William P. Murphy Jr., M.D.
10.11(4)	Loan Agreement, dated as of June 1, 2007, by and between the registrant and Bank of America, N.A.
10.13(4)	Warrant to purchase shares of the registrant's common stock issued to Howard J. Leonhardt and Brenda Leonhardt
10.14(4)	Warrant to purchase shares of the registrant's common stock issued to William P. Murphy, Jr., M.D.
10.16(4)	Material Supply Agreement, dated May 10, 2007, by and between the registrant and Biosense Webster
10.17(5)	Warrant to purchase shares of the registrant's common stock issued to BlueCrest Capital Finance, L.P.
10.18(6)	Loan Guarantee, Payment and Security Agreement, dated as of September 12, 2007, by and between the registrant and Samuel S. Ahn, M.D.
10.19(6)	Loan Guarantee, Payment and Security Agreement, dated as of September 12, 2007, by and between the registrant and Dan Marino
10.21(6)	Loan Guarantee, Payment and Security Agreement, dated as of September 19, 2007, by and between the registrant and Jason Taylor
10.22(7)	Loan Guarantee, Payment and Security Agreement, dated as of October 10, 2007, by and between the registrant and Howard and Brenda Leonhardt
10.24(7)	Second Amendment to Loan Guarantee, Payment and Security Agreement, dated as of October 10, 2007, by and between the registrant and Howard and Brenda Leonhardt
10.25(7)	Second Amendment to Loan Guarantee, Payment and Security Agreement, dated as of October 10, 2007, by and between the registrant and William P. Murphy, Jr., M.D.
10.26**(10)	Bioheart, Inc. Omnibus Equity Compensation Plan
10.28(11)	Form of Registration Rights Agreement for October 2008 Private Placement
10.29(19)	10% Convertible Promissory Note Due July 23, 2010, in the amount of $20,000, payable to Dana Smith
10.31(19)	Registration Rights Agreement, dated July 23, 2009
10.32(19)	Subordination Agreement, dated July 23, 2009
10.33(19)	Note Purchase Agreement, dated July 23, 2009
10.34(19)	Closing Confirmation of Conversion Election, dated July 23, 2009
10.35**(20)	Amended and Restated 1999 Directors and Consultants Stock Option Plan
10.36(21)	Preliminary Commitment Letter with Seaside National Bank and Trust, dated September 30, 2010.
10.37(22)	Loan Agreement with Seaside National Bank and Trust, dated October 25, 2010.
10.38(22)	Promissory Note with Seaside National Bank and Trust, dated October 25, 2010.
10.39(22)	Amended and Restated Loan and Security Agreement with BlueCrest Venture Finance Master Fund Limited, dated October 25, 2010.
10.40(23)	Form of Subscription Agreement, executed November 30, 2010.
10.41(23)	Form of Common Stock Purchase Warrant, issued November 30, 2010.
10.42(23)	Form of Registration Rights Agreement, dated November 30, 2010.
10.43(24)	Unsecured Convertible Promissory Note for $25,000, with Magna Group, LLC, dated January 3, 2011.
10.44(24)	Promissory Note for $139,728.82 with Magna Group, LLC, dated January 3, 2011.
10.45(24)	Securities Purchase Agreement with Magna Group, LLC, dated January 3, 2011.
10.46(24)	Subordination Agreement, dated January 3, 2011.
10.47(24)	Notice of Conversion Election, dated January 3, 2011.
10.48(25)	Unsecured Convertible Promissory Note for $34,750, with Magna Group, LLC, dated May 16, 2011.
10.49(25)	Promissory Note for $139,728.82 with Magna Group, LLC, dated May 16, 2011.
10.50(25)	Securities Purchase Agreement with Magna Group, LLC, dated May 16, 2011.
10.51(25)	Subordination Agreement, dated May 16, 2011.
10.52(26)	Promissory Note for $139,728.82 with Lotus Funding Group, LLC, dated June 15, 2011.
10.53(26)	Partial Assignment and Modification Agreement, dated June 15, 2011.
10.54(26)	Subordination Agreement, dated June 15, 2011.
10.55(27)	Promissory Note for $140,380.21 with Greystone Capital Partners, dated July 8, 2011.
10.56(27)	Partial Assignment and Modification Agreement, dated July 8, 2011.

33

10.57(27)	Subordination Agreement, dated July 8, 2011.
10.58(28)	Promissory Note for $139,728.82 with Greystone Capital Partners, dated August 1, 2011.
10.59(28)	Partial Assignment and Modification Agreement, dated August 1, 2011.
10.60(28)	Subordination Agreement, dated August 1, 2011.
10.61(29)	Promissory Note for $139,728.82 with Greystone Capital Partners, dated September 1, 2011.
10.62(29)	Partial Assignment and Modification Agreement, dated September 1, 2011.
10.63(29)	Subordination Agreement, dated September 1, 2011.
10.64(30)	Promissory Note for $139,728.82 with Greystone Capital Partners, dated October 1, 2011.
10.65(30)	Partial Assignment and Modification Agreement, dated October 1, 2011.
10.66(30)	Subordination Agreement, dated October 1, 2011.
10.67(29)	Right of First Refusal with Greystone Capital Partners dated September 28, 2011
10.68(29)	Promissory Note for $35,000 with Thalia Woods Management, Inc. dated September 28, 2011.
10.69(29)	Subordination Agreement, dated September 28, 2011
10.70(31)	Promissory Note for $139,728.82 with Greystone Capital Partners, dated November 1, 2011.
10.71(31)	Partial Assignment and Modification Agreement, dated November 1, 2011.
10.72(31)	Subordination Agreement, dated November 1, 2011.
10.73(32)	Promissory Note for $139,728.82 with Greystone Capital Partners, dated December 1, 2011
10.74(32)	Form of Partial Assignment and Modification Agreement.
10.75(32)	Form of Subordination Agreement.
10.76(31)	Standby Equity Distribution Agreement dated as of November 2, 2011.
10.74(33)	Promissory Note for $139,728.82 with Greystone Capital Partners, dated January 3, 2012
10.75(34)	Promissory Note for $139,728.82 with Mr. Charles Hart and Mr. Greg Knutson dated February 6, 2012.
10.76(36)	Unsecured Convertible Promissory Note for $63,000, with Asher Enterprises, Inc., dated April 2, 2012
10.77(37)	Registration Rights Agreement dated as of November 2, 2011.
10.78(38)	Promissory Note for $139,728.82 with Greystone Capital Partners, dated January 3, 2012
10.79(38)	Promissory Note for $139,728.82 with Mr. Charles Hart and Mr. Greg Knutson dated February 6, 2012
10.80(38)	Unsecured Convertible Promissory Note for $63,000, with Asher Enterprises, Inc. dated April 2, 2012
10.81(38)	Standby Equity Distribution Agreement $50,000 drawdown on November 2, 2012
10.82(38)	Standby Equity Distribution Agreement  $25,000 drawdown on November 14,  2012
10.83(38)	Standby Equity Distribution Agreement $50,000 drawdown on November 20, 2012
10.84 (39)	Unsecured Convertible Promissory Note for $125,000, with IBC Funds, LLC, dated January 10, 2013
10.85 (39)	Unsecured Convertible Promissory Note  for 42,500, with Asher Enterprises, Inc. dated January 23, 2013
10.86(39)	Unsecured Convertible Promissory Note for $37,500, with Asher Enterprises, Inc. dated February 27, 2013
10.87*	2013 Omnibus  Equity Compensation Plan
14.1(2)	Code of Ethics for Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer and persons performing similar functions
14.2(2)	Code of Business Conduct and Ethics
31.1*	Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*	Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

* Filed herewith

** Indicates management contract or compensatory plan.

(1)	Incorporated by reference to the Company’s Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on February 13, 2007.
(2)	Incorporated by reference to Amendment No. 1 to the Company’s Form S-1 filed with the SEC on June 5, 2007.
(3)	Incorporated by reference to Amendment No. 2 to the Company’s Form S-1 filed with the SEC on July 12, 2007.
(4)	Incorporated by reference to Amendment No. 3 to the Company’s Form S-1 filed with the SEC on August 9, 2007.
(5)	Incorporated by reference to Amendment No. 4 to the Company’s Form S-1 filed with the SEC on September 6, 2007.
(6)	Incorporated by reference to Amendment No. 5 to the Company’s Form S-1 filed with the SEC on October 1, 2007.
(7)	Incorporated by reference to Post-effective Amendment No. 1 to the Company’s Form S-1 filed with the SEC on October 11, 2007.
(8)	Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on July 3, 2008.
(9)	Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on August 8, 2008.
(10)	Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2008.

34

(11)	Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 14, 2008.
(13)	Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 8, 2009.
(14)	Incorporated by reference to the Company’s Annual Report on Form 10-K filed with the SEC on April 15, 2009.
(15)	Incorporated by reference to the Company’s Annual Report on Form 10-K/A filed with the SEC on April 30, 2009.
(16)	Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on May 18, 2009.
(17)	Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 20, 2009.
(18)	Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on July 9, 2009.
(19)	Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on August 3, 2009.
(20)	Incorporated by reference to Exhibit 4.6 to the Company’s Post Effective Amendment to Registration Statement on Form S-8/A, filed with the SEC on June 2, 2010.
(21)	Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 6, 2010.
(22)	Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on October 29, 2010.
(23)	Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on December 6, 2010.
(24)	Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on January 12, 2011.
(25)	Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on May 25, 2011
(26)	Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on June 21,2011
(27)	Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 15. 2011
(28)	Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2011
(29)	Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on January 13, 2012
(30)	Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on January 30, 2012
(31)	Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on March 23, 2012
(32)	Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on March 30, 2012
(33)	Incorporated by reference to the Company Current Report on Form 8-K filed with the SEC on April 2, 2012
(34)	Incorporated by reference to the Company’s Annual Report on Form 10-K filed with the SEC on April 12, 2012.
(35)	Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 14, 2012
(36)	Incorporated by reference to the Company’s Current Report on Form 8-K with the SEC on June 26, 2012
(37)	Incorporated by reference to the Company’s Current Report on Form 8-K with the SEC on August 1, 2012

31.1	Section 302 Certification of Principal Executive  and Financial Officer
32.1	Section 906 Certification of Principal Executive and Financial Officer
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Calculation Linkbase Document
101.LAB	XBRL Taxonomy Labels Linkbase Document
101.PRE	XBRL Taxonomy Presentation Linkbase Document
101.DEF	XBRL Definition Linkbase Document

35

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		Bioheart, Inc.
Date: May 9, 2013	By:	/s/Mike Tomas
		Mike Tomas
		Chief Executive Officer & President and Principal Financial and Accounting Officer

36

EX-10.87

EXHIBIT 10.87

2013 Omnibus  Equity Compensation Plan

BIOHEART, INC.

2013 OMNIBUS EQUITY COMPENSATION PLAN

TABLE OF CONTENTS

ARTICLE I	GENERAL PROVISIONS	3
ARTICLE II	DEFINITIONS	3
ARTICLE III	ADMINISTRATION	6
ARTICLE IV	INCENTIVE STOCK OPTIONS	10
ARTICLE V	NONQUALIFIED STOCK OPTIONS	11
ARTICLE VI	STOCK APPRECIATION RIGHTS	12
ARTICLE VII	INCIDENTS OF STOCK OPTIONS AND STOCK RIGHTS	13
ARTICLE VIII	RESTRICTED STOCK	15
ARTICLE IX	DEFERRED STOCK	17
ARTICLE X	STOCK AWARDS	18
ARTICLE XI	PERFORMANCE SHARES	19
ARTICLE XII	OTHER STOCK-BASED AWARDS	20
ARTICLE XIII	ACCELERATION EVENTS	22
ARTICLE XIV	AMENDMENT AND TERMINATION	24
ARTICLE XV	MISCELLANEOUS PROVISIONS	24

2

ARTICLE I

GENERAL PROVISIONS

1.1

The Plan is designed for the benefit of the directors, executives, independent contractors, and key employees of the Company (i) to attract and retain for the Company personnel of exceptional ability; (ii) to motivate such personnel through added incentives to make a maximum contribution to greater profitability; (iii) to develop and maintain a highly competent management team; and (iv) to be competitive with other companies with respect to executive compensation.

1.2

Awards under the Plan may be made to Participants in the form of (i) Incentive Stock Options; (ii) Nonqualified Stock Options; (iii) Stock Appreciation Rights; (iv) Restricted Stock; (v) Deferred Stock; (vi) Stock Awards; (vii) Performance Shares; (viii) Other Stock-Based Awards; and (ix) other forms of equity-based compensation as may be provided and are permissible under this Plan and the law.

1.3

The Plan shall be effective on April 1, 2013 (the “Effective Date”), subject to the approval of the Plan by a majority of the votes cast by the holders of the Company’s Common Stock, which may be voted at the next annual or special shareholder’s meeting. Any Awards granted under the Plan prior to such approval shall be effective when made (unless otherwise specified by the Committee at the time of grant) but shall be conditioned on, and subject to, the approval of the Plan by the Company’s shareholders.

ARTICLE II

DEFINITIONS

Except where the context otherwise indicates, the following definitions apply:

2.1

“Acceleration Event” means the occurrence of an event defined in Article XIII of the Plan.

2.2

“Act” means the Securities Exchange Act of 1934, as amended.

2.3

“Agreement” means the written agreement evidencing each Award granted to a Participant under the Plan.

2.4

“Award” means an award granted to a Participant in accordance with the provisions of the Plan, including, but not limited to, a Stock Option, Stock Right, Restricted or Deferred Stock, Stock Award, Performance Share, Other Stock-Based Award, or any combination of the foregoing.

2.5

“Board” means the Board of Directors of the Company.

2.6

“Change in Control” shall have the meaning set forth in Section 13.2 of the Plan.

2.7

“Change in Control Price” shall have the meaning set forth in Section 13.7 of the Plan.

2.8

“Code” means the Internal Revenue Code of 1986, as amended.

3

2.9

“Committee” means the Compensation Committee of the Board, or in the absence of a Committee, the Board of Directors.

2.10

“Company” means Bioheart, Inc., a Florida corporation.

2.11

“Deferral Period” means the period commencing on the date an Award of Deferred Stock is granted and ending on such date as the Committee shall determine.

2.12

“Deferred Stock” means the stock awarded under Article IX of the Plan.

2.13

“Disability” means disability as determined under procedures established by the Committee or in any Award.

2.14

“Discount Stock Options” means the Nonqualified Stock Options, which provide for an exercise price of less than the Fair Market Value of the Stock at the date of the Award.

2.15

“Early Retirement” means retirement from active employment with the Company, with the express consent of the Committee, pursuant to the early retirement provisions established by the Committee or in any Award.

2.16

“Effective Date” shall have the meaning set forth in Section 1.3 of the Plan.

2.17

“Elective Deferral Period” shall have the meaning set forth in Section 9.3 of the Plan.

2.18

“Eligible Participant” means any director, executive or key employee of the Company, as shall be determined by the Committee, as well as any other person whose participation the Committee determines is in the best interest of the Company, subject to limitations as may be provided by the Code, the Act or the Committee. For purposes of Article IV and Incentive Stock Options that may be granted hereunder, the term “Eligible Participant” shall be limited to an executive or other key employee meeting the qualifications for receipt of an Incentive Stock Option under the provisions of Section 422 of the Code.

2.19

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended.

2.20

“Fair Market Value” means, with respect to any given day, the closing price of the Stock reported on the Nasdaq Global Market tier of The Nasdaq Stock Market for such day, or if the Stock was not traded on the Nasdaq Global Market tier of The Nasdaq Stock Market on such day, then on the next day on which the Stock was traded, all as reported by such source as the Committee may select. The Committee may establish an alternative method of determining Fair Market Value. Notwithstanding the foregoing, the Committee shall, to the extent Section 409A of the Code applies, use a valuation method that satisfies Section 409A and any regulations thereunder.

2.21

“Incentive Stock Option” means a Stock Option granted under Article IV of the Plan, and as defined in Section 422 of the Code.

2.22

“Limited Stock Appreciation Rights” means a Stock Right which is exercisable only in the event of a Change in Control, as described in Section 6.8 of this Plan, which provides for an amount payable solely in cash, equal to the excess of the Stock Appreciation Right Fair Market Value of a share of Stock on the day the Stock Right is surrendered over the price at which a Participant could exercise a related Stock Option to purchase the share of Stock.

4

2.23

“Nonqualified Stock Option” means a Stock Option granted under Article V of the Plan.

2.24

“Normal Retirement” means retirement from active employment with the Company or any Subsidiary on or after age 65, or pursuant to such other requirements as may be established by the Committee or in any Award.

2.25

“Option Grant Date” means, as to any Stock Option, the latest of:

(a)

the date on which the Committee grants the Stock Option to the Participant;

(b)

the date the Participant receiving the Stock Option becomes an employee of the Company or its Subsidiaries, to the extent employment status is a condition of the grant or a requirement of the Code or the Act; or

(c)

such other date (other than the dates described in (i) and (ii) above) as the Committee may designate.

2.26

“Other Stock-Based Award” means an Award under Article XII of the Plan that is valued in whole or in part by reference to, or is otherwise based on, Stock.

2.27

“Participant” means an Eligible Participant to whom an Award of equity-based compensation has been granted and who has entered into an Agreement evidencing the Award.

2.28

“Performance Share” means an Award under Article XI of the Plan of a unit valued by reference to a designated number of shares of Stock, which value may be paid to the Participant by delivery of such property as the Committee shall determine, including, without limitation, cash, Stock, or any combination thereof, upon achievement of such Performance Objectives during the Performance Period as the Committee shall establish at the time of such Award or thereafter.

2.29

“Performance Objectives” shall have the meaning set forth in Article XI of the Plan.

2.30

“Performance Period” shall have the meaning set forth in Article XI of the Plan.

2.31

“Plan” means the Bioheart, Inc. Omnibus Equity Compensation Plan, as amended from time to time.

2.32

“Related Stock Appreciation Right” shall have the meaning set forth in Section 6.1 of the Plan.

2.33

“Restricted Stock” means an Award of Stock under Article VIII of the Plan, which Stock is issued with the restriction that the holder may not sell, transfer, pledge, or assign such Stock and with such other restrictions as the Committee, in its sole discretion, may impose (including, without limitation, any restriction on the right to vote such Stock, and the right to receive any cash dividends), which restrictions may lapse separately or in combination at such time or times, in installments or otherwise, as the Committee may deem appropriate.

5

2.34

“Restriction Period” means the period commencing on the date an Award of Restricted Stock is granted and ending on such date as the Committee shall determine.

2.35

“Retirement” means Normal or Early Retirement.

2.36

“Stock” means shares of common stock par value $.001 per share of the Company, as may be adjusted pursuant to the provisions of Section 3.10.

2.37

“Stock Appreciation Right” means a Stock Right, as described in Article VI of this Plan, which provides for an amount payable in Stock and/or cash, as determined by the Committee, equal to the excess of the Fair Market Value of a share of Stock on the day the Stock Right is exercised over the price at which the Participant could exercise a related Stock Option to purchase the share of Stock; provided that, such price shall not be less than one hundred percent (100%) of the Fair Market Value of the Stock on the date of grant.

2.38

“Stock Appreciation Right Fair Market Value” means a value established by the Committee for the exercise of a Stock Appreciation Right or a Limited Stock Appreciation Right.

2.39

“Stock Award” means an Award of Stock granted in payment of compensation, as provided in Article X of the Plan.

2.40

“Stock Option” means an Award under Article IV or V of the Plan of an option to purchase Stock. A Stock Option may be either an Incentive Stock Option or a Nonqualified Stock Option.

2.41

“Stock Right” means an Award under Article VI of the Plan. A Stock Right may be either a Stock Appreciation Right or a Limited Stock Appreciation Right.

2.42

“Termination of Employment” means the discontinuance of employment of a Participant with the Company. The determination of whether a Participant has discontinued employment shall be made by the Committee in its discretion. In determining whether a Termination of Employment has occurred, the Committee may provide that service as a consultant or service with a business enterprise in which the Company has a significant ownership interest shall be treated as employment with the Company. The Committee shall have the discretion, exercisable either at the time the Award is granted or at the time the Participant terminates employment, to establish as a provision applicable to the exercise of one or more Awards that during the limited period of exercisability following Termination of Employment, the Award may be exercised not only with respect to the number of shares of Stock for which it is exercisable at the time of the Termination of Employment but also with respect to one or more subsequent installments for which the Award would have become exercisable had the Termination of Employment not occurred. Notwithstanding the foregoing, Termination of Employment shall, for purposes of any payment under an Award to which Section 409A of Code applies, have the same meaning as “separation from service” under Section 409A (and any regulations thereunder).

ARTICLE III

ADMINISTRATION

3.1

This Plan shall be administered by the Committee. Members of the Committee may vote on any matters affecting the administration of the Plan or the grant of Awards pursuant to the Plan, except that no such member shall act upon the granting of an Award to himself or herself, but any such member may be counted in determining the existence of a quorum at any meeting of the Committee or Board during which action is taken with

6

respect to the granting of an Award to such member. The Committee, in its discretion, may delegate to one or more of its members such of its powers, as it deems appropriate. The Committee also may limit the power of any member to the extent necessary to comply with Rule 16b-3 under the Act or any other law. The Board, in its discretion, may require that all or any final actions or determinations by the Committee be made by or be subject to approval or ratification by the Board before becoming effective. To the extent all or any decisions, actions, or determinations relating to the administration of the Plan are made by the Board, the Board shall have all power and authority granted to the Committee in this Article and otherwise in this Plan, and for these purposes, all references to the “Committee” herein shall be deemed to include the Board.

3.2

The Committee shall have the exclusive right to interpret, construe and administer the Plan, to select the persons who are eligible to receive an Award, and to act in all matters pertaining to the granting of an Award and the contents of the Agreement evidencing the Award, including, without limitation, the determination of the number of Stock Options, Stock Rights, shares of Stock or Performance Shares subject to an Award and the form, terms, conditions and duration of each Award, and any amendment thereof consistent with the provisions of the Plan. All acts, determinations and decisions of the Committee made or taken pursuant to grants of authority under the Plan or with respect to any questions arising in connection with the administration and interpretation of the Plan, including the severability of any and all of the provisions thereof, shall be conclusive, final and binding upon all Participants, Eligible Participants and their beneficiaries.

3.3

The Committee may adopt such rules, regulations and procedures of general application for the administration of this Plan, as it deems appropriate.

3.4

Without limiting the foregoing Sections 3.1, 3.2 and 3.3, and notwithstanding any other provisions of the Plan, the Committee is authorized to take such action as it determines to be necessary or advisable, and fair and equitable to Participants, with respect to an Award in the event of an Acceleration Event as defined in Article XIII. Such action may include, but shall not be limited to, establishing, amending or waiving the forms, terms, conditions and duration of an Award and the Award Agreement, so as to provide for earlier, later, extended or additional times for exercise or payments, differing methods for calculating payments, alternate forms and amounts of payment, an accelerated release of restrictions or other modifications. The Committee may take such actions pursuant to this Section 3.4 by adopting rules and regulations of general applicability to all Participants or to certain categories of Participants, by including, amending or waiving terms and conditions in an Award and the Award Agreement, or by taking action with respect to individual Participants.

3.5

The aggregate number of shares of Stock, which are reserved for issuance under the Plan, shall be fifty million (50,000,000). The aggregate number of shares of stock reserved for issuance under the plan shall be adjusted in accordance with Section 3.10.

(a)

If, for any reason, any shares of Stock or Performance Shares awarded or subject to purchase under the Plan are not delivered or purchased, or are reacquired by the Company, for reasons including, but

not limited to, a forfeiture of Restricted Stock or termination, expiration or cancellation of a Stock Option, Stock Right or Performance Share, or any other termination of an Award without payment being made in the form of Stock (whether or not Restricted Stock), such shares of Stock or Performance Shares shall not be charged against the aggregate number of shares of Stock available for Award under the Plan, and shall again be available for Award under the Plan.

(b)

For all purposes under the Plan, each Performance Share awarded shall be counted as one share of Stock subject to an Award.

7

(c)

To the extent a Stock Right granted in connection with a Stock Option is exercised without payment being made in the form of Stock (whether or not Restricted Stock), the shares of Stock which otherwise would have been issued upon the exercise of such related Stock Option shall not be charged against the aggregate number of shares of Stock subject to an Award under the Plan, and shall again be available for Award under the Plan.

3.6

Each Award granted under the Plan shall be evidenced by a written Award Agreement. Each Award Agreement shall be subject to and incorporate (by reference or otherwise) the applicable terms and conditions of the Plan, and any other terms and conditions (not inconsistent with the Plan) required by the Committee.

3.7

The Company shall not be required to issue or deliver any certificates for shares of Stock prior to:

(a)

the listing of such shares on any stock exchange on which the Stock may then be listed; and

(b)

the completion of any registration or qualification of such shares of Stock under any federal or state law, or any ruling or regulation of any government body which the Company shall, in its discretion, determine to be necessary or advisable.

3.8

All certificates for shares of Stock delivered under the Plan shall also be subject to such stop-transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations, and other requirements of the Securities and Exchange Commission, any stock exchange upon which the Stock is then listed and any applicable federal or state laws, and the Committee may cause a legend or legends to be placed on any such certificates to make appropriate reference to such restrictions. In making such determination, the Committee may rely upon an opinion of counsel for the Company.

3.9

Subject to the restrictions on Restricted Stock, as provided in Article VIII of the Plan and in the Restricted Stock Award Agreement, each Participant who receives an Award of Restricted Stock shall have all of the rights of a shareholder with respect to such shares of Stock, including the right to vote the shares to the extent, if any, such shares possess voting rights and receive dividends and other distributions. Except as provided otherwise in the Plan or in an Award Agreement, no Participant awarded a Stock Option, Stock Right, Deferred Stock, Stock Award or Performance Share shall have any right as a shareholder with respect to any shares of Stock covered by his or her Stock Option, Stock Right, Deferred Stock, Stock Award or Performance Share prior to the date of issuance to him or her of a certificate or certificates for such shares of Stock.

3.10

If any reorganization, recapitalization, reclassification, stock split-up, stock dividend, or consolidation of shares of Stock, merger or consolidation of the Company or its Subsidiaries or sale or other disposition by the Company or its Subsidiaries of all or a portion of its assets, any other change in the Company’s or its Subsidiaries’ corporate structure, or any distribution to shareholders other than a cash dividend results in the outstanding shares of Stock, or any securities exchanged therefor or received in their place, being exchanged for a different number or class of shares of Stock or other securities of the Company, or for shares of Stock or other securities of any other Company; or new, different or additional shares or other securities of the Company or of any other Company being received by the holders of outstanding shares of Stock, then equitable adjustments shall be made by the Committee in:

8

(a)

the limitation of the aggregate number of shares of Stock that may be awarded as set forth in Sections 3.5, 3.15, and 4.1(e) (to the extent permitted under Section 422 of the Code) of the Plan;

(b)

the number of shares and class of Stock that may be subject to an Award, and which have not been issued or transferred under an outstanding Award;

(c)

the purchase price to be paid per share of Stock under outstanding Stock Options and the number of shares of Stock to be transferred in settlement of outstanding Stock Rights; and

(d)

the terms, conditions or restrictions of any Award and Award Agreement, including the price payable for the acquisition of Stock; provided, however, that all adjustments made as the result of the foregoing in respect of (i) each Incentive Stock Option shall be made so that such Stock Option shall continue to be an Incentive Stock Option, as defined in Section 422 of the Code and (ii) any Award that is subject to Section 409A of the Code shall comply with Section 409A and any regulations thereunder.

3.11

In addition to such other rights of indemnification as they may have as directors or as members of the Committee, the members of the Committee shall be indemnified by the Company against reasonable expenses, including attorney’s fees, actually and necessarily incurred in connection with the defense of any action, suit or proceeding, or in connection with any appeal therein, to which they or any of them may be a party by reason of any action taken or failure to act under or in connection with the Plan or any Award granted thereunder, and against all amounts paid by them in settlement thereof (provided such settlement is approved by independent legal counsel selected by the Company) or paid by them in satisfaction of a judgment or settlement in any such action, suit or proceeding, except as to matters as to which the Committee member has been negligent or engaged in misconduct in the performance of his duties; provided, that within sixty (60) days after institution of any such action, suit or proceeding, a Committee member shall in writing offer the Company the opportunity, at its own expense, to handle and defend the same. Any payments required under this Section 3.11 that are subject to Section 409A of the Code shall be made by the end of year following the year in which the expenses and liabilities were incurred.

3.12

The Committee may require each person purchasing shares of Stock pursuant to a Stock Option or other Award under the Plan to represent to and agree with the Company in writing that he is acquiring the shares of Stock without a view to distribution thereof. The certificates for such shares of Stock may include any legend, which the Committee deems appropriate to reflect any restrictions on transfer.

3.13

The Committee shall be authorized to make adjustments in a performance based criteria or in the terms and conditions of other Awards in recognition of unusual or nonrecurring events affecting the Company or its financial statements or changes in applicable laws, regulations or accounting principles. The Committee may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award Agreement in the manner and to the extent it shall deem desirable to carry it into effect or comply with applicable law. In the event the Company (or any Subsidiary, if applicable) shall assume outstanding employee benefit awards or the right or obligation to make future such awards in connection with the acquisition of another Company or business entity, the Committee may, in its discretion, make such adjustments in the terms of Awards under the Plan as it shall deem appropriate.

3.14

The Committee shall have full power and authority to determine whether, to what extent and under what circumstances, any Award shall be canceled or suspended. In particular, but without limitation, all outstanding Awards to any Participant shall be canceled if (a) the Participant, without the consent of the Committee, while

9

employed by the Company or after termination of such employment, becomes associated with, employed by, renders services to, or owns any interest in (other than any non-substantial interest, as determined by the Committee), any business that is in competition with the Company or with any business in which the Company has a substantial interest as determined by the Committee; or (b) is terminated for cause as determined by the Committee.

ARTICLE IV

INCENTIVE STOCK OPTIONS

4.1

Each provision of this Article IV and of each Incentive Stock Option granted hereunder shall be construed in accordance with the provisions of Section 422 of the Code, and any provision hereof that cannot be so construed shall be disregarded. Incentive Stock Options shall be granted only to Eligible Participants, each of whom may be granted one or more such Incentive Stock Options at such time or times determined by the Committee following the Effective Date until the ten (10) year anniversary of the Effective Date, subject to the following conditions:

(a)

The Incentive Stock Option price per share of Stock shall be set in the Award Agreement, but shall not be less than one hundred percent (100%) of the Fair Market Value of the Stock at the time of the Option Grant Date.

(b)

The Incentive Stock Option and its related Stock Right, if any, may be exercised in full or in part from time to time within ten (10) years from the Option Grant Date, or such shorter period as may be specified by the Committee in the Award; provided, that in any event, the Incentive Stock Option and related Stock Right shall lapse and cease to be exercisable upon, or within such period following, a Termination of Employment as shall have been determined by the Committee and as specified in the Incentive Stock Option Award Agreement or its related Stock Right Award Agreement; provided, however, that such period following a Termination of Employment shall not exceed three (3) months unless employment shall have terminated:

(i)

as a result of death or Disability, in which event, such period shall not exceed one year after the date of death or Disability; and

(ii)

as a result of death, if death shall have occurred following a Termination of Employment and while the Incentive Stock Option or Stock Right was still exercisable, in which event, such period shall not exceed one year after the date of death; provided, further, that such period following a Termination of Employment shall in no event extend the original exercise period of the Incentive Stock Option or any related Stock Right.

(c)

The aggregate Fair Market Value, determined as of the Option Grant Date, of the shares of Stock with respect to which Incentive Stock Options are exercisable for the first time during any calendar year by any Eligible Participant shall not exceed one hundred thousand dollars ($100,000); provided, however, to the extent permitted under Section 422 of the Code:

(i)

if a Participant’s employment is terminated by reason of death, Disability or Retirement and the portion of any Incentive Stock Option that is otherwise exercisable during the post-termination period applied without regard to the one hundred thousand dollar ($100,000) limitation contained in Section 422 of the Code is greater than the portion of such option that is immediately exercisable as an Incentive Stock Option

10

during such post-termination period under Section 422, such excess shall be treated as a Nonqualified Stock Option; and

(ii)

if the exercise of an Incentive Stock Option is accelerated by reason of an Acceleration Event, any portion of such Award that is not exercisable as an Incentive Stock Option by reason of the one hundred thousand dollar ($100,000) limitation contained in Section 422 of the Code shall be treated as a Nonqualified Stock Option. Notwithstanding the foregoing, no Stock Option that is intended to be an Incentive Stock Option shall be invalid for failure to qualify as such and the Company shall honor any such stock Option as a Nonqualified Stock Option.

(d)

Incentive Stock Options shall be granted only to an Eligible Participant who, at the time of the Option Grant Date, does not own Stock possessing more than 10% of the total combined voting power of all classes of stock of the Company; provided, however, the foregoing restriction shall not apply if at the time of the Option Grant Date the option price is at least one hundred ten percent (110%) of the Fair Market Value of the Stock subject to the Incentive Stock Option and such Incentive Stock Option by its terms is not exercisable after the expiration of five (5) years from the Option Grant Date.

(e)

The Committee may adopt any other terms and conditions which it determines should be imposed for the Incentive Stock Option to qualify under Section 422 of the Code, as well as any other terms and conditions not inconsistent with this Article IV as determined by the Committee.

4.2

The Committee may at any time offer to buy out for a payment in cash, Stock, Deferred Stock or Restricted Stock an Incentive Stock Option previously granted, based on such terms and conditions as the Committee shall establish and communicate to the Participant at the time that such offer is made.

4.3

If the Incentive Stock Option Award Agreement so provides, the Committee may, to the extent consistent with Section 409A of the Code (and any regulations thereunder), require that all or part of the shares of Stock to be issued upon the exercise of an Incentive Stock Option shall take the form of Deferred or Restricted Stock, which shall be valued on the date of exercise, as determined by the Committee, on the basis of the Fair Market Value of such Deferred Stock or Restricted Stock determined without regard to the deferral limitations and/or forfeiture restrictions involved.

ARTICLE V

NONQUALIFIED STOCK OPTIONS

5.1

One or more Stock Options may be granted as Nonqualified Stock Options to Eligible Participants to purchase shares of Stock at such time or times determined by the Committee, following the Effective Date, subject to the terms and conditions set forth in this Article V.

5.2

The Nonqualified Stock Option price per share of Stock shall be established in the Award Agreement, but shall not be less than one hundred percent (100%) of the Fair Market Value of the Stock on the Option Grant Date.

5.3

The Nonqualified Stock Option and its related Stock Right, if any, may be exercised in full or in part from time to time within such period as may be specified by the Committee or in the Award Agreement; provided, that, in any event, the Nonqualified Stock Option and the related Stock Right shall lapse and cease to be exercisable upon, or within such period following, Termination of Employment as shall have been determined by

11

the Committee and as specified in the Nonqualified Stock Option Award Agreement or Stock Right Award Agreement; provided, however, that such period following Termination of Employment shall not exceed three (3) months unless employment shall have terminated:

(a)

as a result of Retirement or Disability, in which event, such period shall not exceed one year after the date of Retirement or Disability, or within such longer period as the Committee may specify; and

(b)

as a result of death, or if death shall have occurred following a Termination of Employment and while the Nonqualified Stock Option or Stock Right was still exercisable, in which event, such period may exceed one year after the date of death, as provided by the Committee or in the Award Agreement.

5.4

The Nonqualified Stock Option Award Agreement may include any other terms and conditions not inconsistent with this Article V or with Article VII, as determined by the Committee.

ARTICLE VI

STOCK APPRECIATION RIGHTS

6.1

A Stock Appreciation Right may be granted to an Eligible Participant in connection with an Incentive Stock Option or a Nonqualified Stock Option granted under Article IV or Article V of this Plan (a “Related Stock Appreciation Right”), or may be granted independent of any related Incentive or Nonqualified Stock Option.

6.2

A Related Stock Appreciation Right shall entitle a holder of a Stock Option, within the period specified for the exercise of the Stock Option, to surrender the unexercised Stock Option (or a portion thereof) and to receive in exchange therefor a payment in cash or shares of Stock having an aggregate value equal to the amount by which the Fair Market Value of each share of Stock exceeds the Stock Option price per share of Stock, times the number of shares of Stock under the Stock Option, or portion thereof, which is surrendered.

6.3

Each Related Stock Appreciation Right granted hereunder shall be subject to the same terms and conditions as the related Stock Option, including limitations on transferability, if any, and shall be exercisable only to the extent such Stock Option is exercisable and shall terminate or lapse and cease to be exercisable when the related Stock Option terminates or lapses. The grant of a Related Stock Appreciation Right related to an Incentive Stock Option must be concurrent with the grant of the Incentive Stock Option. With respect to Nonqualified Stock Options, the grant of a Related Stock Appreciation Right either may be concurrent with the grant of the Nonqualified Stock Option, or (to the extent consistent with the exemption for stock appreciation rights under the Section 409A regulations) subsequent to the grant of the Nonqualified Stock Option, in connection with a Nonqualified Stock Option previously granted under Article V, which is unexercised and has not terminated or lapsed.

6.4

The Committee shall have the sole discretion to determine, in each case whether the payment with respect to the exercise of a Stock Appreciation Right shall be made in the form of all cash, all Stock, or any combination thereof. If payment is to be made in Stock, the number of shares of Stock shall be determined based on the Fair Market Value of the Stock on the date of exercise of the Stock Appreciation Right. If the Committee elects to make full payment in Stock, no fractional shares of Stock shall be issued and cash payments shall be made in lieu of fractional shares.

12

6.5

The Committee shall have sole discretion as to the timing of any payment made in cash, Stock, or a combination thereof upon exercise of a Stock Appreciation Right. Payment may, to the extent consistent with Section 409A of the Code (and any regulations thereunder), be made in a lump sum, in annual installments or may be otherwise deferred and the Committee shall have sole discretion to determine whether any deferred payments may bear amounts equivalent to interest or cash dividends.

6.6

Upon the exercise of a Related Stock Appreciation Right, the number of shares of Stock subject to exercise under any related Stock Option shall automatically be reduced by the number of shares of Stock represented by the Stock Option or portion thereof which is surrendered.

6.7

The Committee, in its sole discretion, may, to the extent consistent with the exemption for stock appreciation rights under the Section 409A regulations, also provide that, in the event of a Change in Control, the amount to be paid upon the exercise of a Stock Appreciation Right or Limited Stock Appreciation Right shall be based on the Change in Control Price, subject to such terms and conditions as the Committee may specify at grant.

6.8

In its sole discretion, the Committee may grant Limited Stock Appreciation Rights under this Article VI. Limited Stock Appreciation Rights shall become exercisable only in the event of a Change in Control, subject to such terms and conditions as the Committee, in its sole discretion, may specify at grant. Such Limited Stock Appreciation Rights shall be settled solely in cash. A Limited Stock Appreciation Right shall entitle the holder of the related Stock Option to surrender such Stock Option, or any portion thereof, to the extent unexercised, in respect of the number of shares of Stock as to which such Limited Stock Appreciation Right is exercised, and to receive a cash payment equal to the difference between (a) the Stock Appreciation Right Fair Market Value (at the date of surrender) of a share of Stock for which the surrendered Stock Option or portion thereof is then exercisable, and (b) the price at which a Participant could exercise a related Stock Option to purchase the share of Stock. Such Stock Option shall, to the extent so surrendered, thereupon cease to be exercisable. A Limited Stock Appreciation Right shall be subject to such further terms and conditions as the Committee shall, in its sole discretion, deem appropriate.

ARTICLE VII

INCIDENTS OF STOCK OPTIONS AND STOCK RIGHTS

7.1

Each Stock Option and Stock Right shall be granted subject to such terms and conditions, if any, not inconsistent with this Plan, as shall be determined by the Committee, including any provisions as to continued employment as consideration for the grant or exercise of such Stock Option or Stock Right and any provisions which may be advisable to comply with applicable laws, regulations or rulings of any governmental authority.

7.2

An Incentive Stock Option and its related Stock Right, if any, shall not be transferable by the Participant other than by will or by the laws of descent and distribution, and shall be exercisable during the lifetime of the Participant only by him or by his guardian or legal representative. A Nonqualified Stock Option and its related Stock Right, if any, shall be subject to the transferability and exercisability restrictions of the immediately preceding sentence unless otherwise determined by the Committee, in its sole discretion, and set forth in the applicable Award Agreement.

7.3

Shares of Stock purchased upon exercise of a Stock Option shall be paid for in such amounts, at such times and upon such terms as shall be determined by the Committee, subject to limitations set forth in the Stock

13

Option Award Agreement. Without limiting the foregoing, the Committee may establish payment terms for the exercise of Stock Options which permit the Participant to deliver shares of Stock (or other evidence of ownership of Stock satisfactory to the Company) with a Fair Market Value equal to the exercise price of the Stock Option as payment.

7.4

No cash dividends shall be paid on shares of Stock subject to unexercised Stock Options. To the extent consistent with the exemption for stock options under the Section 409A regulations (if applicable), the Committee may provide, however, that a Participant to whom a Stock Option has been granted which is exercisable in whole or in part at a future time shall be entitled to receive an amount per share equal in value to the cash dividends, if any, paid per share on issued and outstanding Stock, as of the dividend record dates occurring during the period between the date of the grant and the time each such share of Stock is delivered pursuant to exercise of such Stock Option or the related Stock Right. Such amounts (herein called “dividend equivalents”) may, in the discretion of the Committee, be:

(a)

paid in cash or Stock either from time to time prior to, or at the time of the delivery of, such Stock, or upon expiration of the Stock Option if it shall not have been fully exercised; or

(b)

converted into contingently credited shares of Stock (with respect to which dividend equivalents may accrue) in such manner, at such value, and deliverable at such time or times, as may be determined by the Committee. Such Stock (whether delivered or contingently credited) shall be charged against the limitations set forth in Section 3.5.

7.5

The Committee may, in its sole discretion consistent with Section 409A of the Code (and any regulations thereunder), authorize payment of interest equivalents on dividend equivalents which are payable in cash at a future time.

7.6

In the event of death or Disability, the Committee, with the consent of the Participant or his legal representative, may authorize payment, in cash or in Stock, or partly in cash and partly in Stock, as the Committee may direct, of an amount equal to the difference at the time between the Fair Market Value of the Stock subject to a Stock Option and the exercise price of the Option in consideration of the surrender of the Stock Option.

7.7

If a Participant is required to pay to the Company an amount with respect to income and employment tax withholding obligations in connection with exercise of a Nonqualified Stock Option and/or with respect to certain dispositions of Stock acquired upon the exercise of an Incentive Stock Option, the Committee, in its discretion and subject to such rules as it may adopt, may permit the Participant to satisfy the obligation, in whole or in part, by making an irrevocable election that a portion of the total Fair Market Value of the shares of Stock subject to the Nonqualified Stock Option and/or with respect to certain dispositions of Stock acquired upon the exercise of an Incentive Stock Option, be paid in the form of cash in lieu of the issuance of Stock and that such cash payment be applied to the satisfaction of the withholding obligations. The amount to be withheld shall not exceed the statutory minimum Federal and State income and employment tax liability arising from the Stock Option exercise transaction.

7.8

The Committee may, to the extent consistent with the exemption for stock options under the Section 409A regulations (if applicable), permit the voluntary surrender of all or a portion of any Stock Option granted under the Plan to be conditioned upon the granting to the Participant of a new Stock Option for the same or a different number of shares of Stock as the Stock Option surrendered, or may require such voluntary surrender as a

14

condition precedent to a grant of a new Stock Option to such Participant. Subject to the provisions of the Plan, such new Stock Option shall be exercisable at the same price, during such period and on such other terms and conditions as are specified by the Committee at the time the new Stock Option is granted. Upon surrender, the Stock Options surrendered shall be canceled and the shares of Stock previously subject to them shall be available for the grant of Awards under the Plan.

ARTICLE VIII

RESTRICTED STOCK

8.1

Restricted Stock Awards may be made to certain Participants as an incentive for the performance of future services that will contribute materially to the successful operation of the Company. Awards of Restricted Stock may be made either alone, in addition to or in conjunction with other Awards granted under the Plan and/or cash payments made outside of the Plan.

8.2

With respect to Awards of Restricted Stock, the Committee shall:

(a)

determine the purchase price, if any, to be paid for such Restricted Stock, which may be equal to or less than par value and may be zero, subject to such minimum consideration as may be required by applicable law;

(b)

determine the length of the Restriction Period;

(c)

determine any restrictions applicable to the Restricted Stock such as service or performance, other than those set forth in this Article VIII;

(d)

determine if the restrictions shall lapse as to all shares of Restricted Stock at the end of the Restriction Period or as to a portion of the shares of Restricted Stock in installments during the Restriction Period; and

(e)

determine if dividends and other distributions on the Restricted Stock are to be paid currently to the Participant or withheld by the Company for the account of the Participant.

8.3

Awards of Restricted Stock must be accepted within a period of sixty (60) days (or such other period as the Committee may specify) after the date of the Award of Restricted Stock, by executing a Restricted Stock Award Agreement and paying whatever price (if any) is required. The prospective recipient of a Restricted Stock Award shall not have any rights with respect to such Award, unless such recipient has executed a Restricted Stock Award Agreement and has delivered a fully executed copy thereof to the Committee, and has otherwise complied with the applicable terms and conditions of such Award.

8.4

Except when the Committee determines otherwise, or as otherwise provided in the Restricted Stock Award Agreement, if a Participant terminates employment with the Company for any reason before the expiration of the Restriction Period, all shares of Restricted Stock still subject to restriction shall be forfeited by the Participant and shall be reacquired by the Company.

15

8.5

Except as otherwise provided in this Article VIII, no shares of Restricted Stock received by a Participant shall be sold, exchanged, transferred, pledged, hypothecated or otherwise disposed of during the Restriction Period.

8.6

To the extent not otherwise provided in a Restricted Stock Award Agreement, in cases of death, Disability or Retirement or in cases of special circumstances, the Committee, if it finds that a waiver would be appropriate, may elect to waive any or all remaining restrictions with respect to such Participant’s Restricted Stock.

8.7

In the event of hardship or other special circumstances of a Participant whose employment with the Company is involuntarily terminated (other than for cause), the Committee may waive in whole or in part any or all remaining restrictions with respect to any or all of the Participant’s Restricted Stock, based on such factors and criteria as the Committee may deem appropriate.

8.8

The certificates representing shares of Restricted Stock may either:

(a)

be held in custody by the Company until the Restriction Period expires or until restrictions thereon otherwise lapse, and the Participant shall deliver to the Company a stock power endorsed in blank relating to the Restricted Stock; and/or

(b)

be issued to the Participant and registered in the name of the Participant, and shall bear an appropriate restrictive legend and shall be subject to appropriate stop-transfer orders.

8.9

Except as provided in this Article VIII, a Participant receiving a Restricted Stock Award shall have, with respect to the shares of Restricted Stock covered by any Award, all of the rights of a shareholder of the Company, including the right to vote the shares to the extent, if any, such shares possess voting rights, and the right to receive any dividends; provided, however, the Committee may, to the extent consistent with Section 409A of the Code (and any regulations thereunder), require that any dividends on such shares of Restricted Stock shall be automatically deferred and reinvested in additional Restricted Stock subject to the same restrictions as the underlying Award, or may require that dividends and other distributions on Restricted Stock shall be withheld by the Company for the account of the Participant. The Committee shall determine whether interest shall be paid on amounts withheld, the rate of any such interest, and the other terms applicable to such withheld amounts.

8.10

If and when the Restriction Period expires without a prior forfeiture of the Restricted Stock subject to such Restriction Period, unrestricted certificates for such shares shall be delivered to the Participant.

8.11

In order to better ensure that Award grants actually reflect the performance of the Company and the service of the Participant, the Committee may provide, in its sole discretion, for a tandem performance-based or other Award designed to guarantee a minimum value, payable in cash or Stock to the recipient of a Restricted Stock Award, subject to such performance, future service, deferral and other terms and conditions as may be specified by the Committee consistent (where applicable) with Section 409A of the Code (and any regulations thereunder).

16

ARTICLE IX

DEFERRED STOCK

9.1

Shares of Deferred Stock (together with cash dividend equivalents, if so determined by the Committee) may be issued either alone or in addition to other Awards granted under the Plan in the discretion of the Committee. The Committee shall determine the individuals to whom, and the time or times at which, such Awards will be made, the number of shares to be awarded, the price (if any) to be paid by the recipient of a Deferred Stock Award, the time or times within which such Awards may be subject to forfeiture, and all other conditions of the Awards. The Committee may condition Awards of Deferred Stock upon the attainment of specified performance goals or such other factors or criteria as the Committee may determine. Any such Award that is subject to Section 409A of the Code shall comply with the applicable deferral, distribution timing and other applicable rules under Section 409A (and any regulations thereunder).

9.2

Deferred Stock Awards shall be subject to the following terms and conditions:

(a)

Subject to the provisions of this Plan and the applicable Deferred Stock Award Agreement, Deferred Stock Awards may not be sold, transferred, pledged, assigned or otherwise encumbered during the Deferral Period. At the expiration of the Deferral Period (or the Elective Deferral Period defined in Section 9.3), share certificates shall be delivered to the Participant, or his legal representative, in a number equal to the number of shares of Stock covered by the Deferred Stock Award. Notwithstanding the foregoing, based on service, performance and/or such other factors or criteria as the Committee may determine, the Committee, at or after the date of the grant, may accelerate the vesting of all or any part of any Deferred Stock Award and/or waive the deferral limitations for all or any part of such Deferred Stock Award.

(b)

Unless otherwise determined by the Committee, amounts equal to any dividends that would have been payable during the Deferral Period with respect to the number of shares of Stock covered by a Deferred Stock Award if such shares of Stock had been outstanding shall be automatically deferred and deemed to be reinvested in additional Deferred Stock, subject to the same deferral limitations as the underlying Deferred Stock Award.

(c)

Except to the extent otherwise provided in this Plan or in the applicable Deferred Stock Award Agreement, upon Termination of Employment during the Deferral Period for a given Award, the Deferred Stock covered by such Award shall be forfeited by the Participant; provided, however, the Committee may provide for accelerated vesting in the event of Termination of Employment due to death, Disability or Retirement, or in the event of hardship or other special circumstances as the Committee deems appropriate.

(d)

The Committee may require that a designated percentage of the total Fair Market Value of the shares of Deferred Stock held by one or more Participants be paid in the form of cash in lieu of the issuance of Stock and that such cash payment be applied to the satisfaction of the federal and state income and employment tax withholding obligations that arise at the time the Deferred Stock becomes free of all restrictions; provided, that for any Award of Deferred Shares subject to Section 409A of the Code, any such offset or payment may only be made to the extent permitted under Section 409A (or any regulations thereunder). The designated percentage shall be equal to the income and employment tax withholding rate in effect at the time under federal and applicable state laws.

17

(e)

The Committee may provide one or more Participants subject to the mandatory cash payment with an election to receive an additional percentage of the total value of the Deferred Stock in the form of a cash payment in lieu of the issuance of Deferred Stock. The additional percentage shall not exceed the difference between fifty percent (50%) and the designated percentage cash payment.

(f)

The Committee may impose such further terms and conditions on partial cash payments with respect to Deferred Stock as it deems appropriate.

9.3

A Participant may elect to further defer receipt of Deferred Stock for a specified period or until a specified event (the “Elective Deferral Period”), subject in each case to the Committee’s approval and to such terms as are determined by the Committee consistent with Section 409A of the Code. Such election must be made at such time as may be permitted under Section 409A (and any regulations thereunder). The deferral of any Award under this Section 9.3 shall comply and be administered consistent with Section 409A. Notwithstanding anything herein to the contrary, in no event will any deferral of any Award be allowed if the Committee determines that the deferral would result in a violation of the requirements of Section 409A for deferral elections and/or the timing of payments. Any deferral election may be reformed by the Committee to the extent necessary or appropriate to comply with the requirements of Section 409A.

9.4

Each Award shall be confirmed by, and subject to the terms of, a Deferred Stock Award Agreement.

9.5

In order to better ensure that the Award actually reflects the performance of the Company and the service of the Participant, the Committee may provide, in its sole discretion consistent with Section 409A of the Code (where applicable), for a tandem performance-based or other Award designed to guarantee a minimum value, payable in cash or Stock to the recipient of a Deferred Stock Award, subject to such performance, future service, deferral and other terms and conditions as may be specified by the Committee.

ARTICLE X

STOCK AWARDS

10.1

A Stock Award shall be granted only in payment of compensation that has been earned or as compensation to be earned, including, without limitation, compensation awarded concurrently with or prior to the grant of the Stock Award.

10.2

For the purposes of this Plan, in determining the value of a Stock Award, all shares of Stock subject to such Stock Award shall be valued at not less than one hundred percent (100%) of the Fair Market Value of such shares of Stock on the date such Stock Award is granted, regardless of whether or when such shares of Stock are issued or transferred to the Participant and whether or not such shares of Stock are subject to restrictions which affect their value.

10.3

Shares of Stock subject to a Stock Award may be issued or transferred to the Participant at the time the Stock Award is granted, or (to the extent consistent with Section 409A of the Code and any regulations thereunder) at any time subsequent thereto or in installments from time to time, as the Committee shall determine. If any such issuance or transfer shall not be made to the Participant at the time the Stock Award is granted, the Committee may provide for payment to such Participant, either in cash or shares of Stock, from time to time or at

18

the time or times such shares of Stock shall be issued or transferred to such Participant, of amounts not exceeding the dividends which would have been payable to such Participant in respect of such shares of Stock (as adjusted under Section 3.10) if such shares of Stock had been issued or transferred to such Participant at the time such Stock Award was granted. Any issuance payable in shares of Stock under the terms of a Stock Award, at the discretion of the Committee, may be paid in cash on each date on which delivery of shares of Stock would otherwise have been made, in an amount equal to the Fair Market Value on such date of the shares of Stock which would otherwise have been delivered.

10.4

A Stock Award shall be subject to such terms and conditions, including, without limitation, restrictions on the sale or other disposition of the Stock Award or of the shares of Stock issued or transferred pursuant to such Stock Award, as the Committee shall determine; provided, however, that upon the issuance or transfer of shares pursuant to a Stock Award, the Participant, with respect to such shares of Stock, shall be and become a shareholder of the Company fully entitled to receive dividends, to vote to the extent, if any, such shares possess voting rights and to exercise all other rights of a shareholder except to the extent otherwise provided in the Stock Award. Each Stock Award shall be evidenced by a written Award Agreement in such form as the Committee shall determine.

ARTICLE XI

PERFORMANCE SHARES

11.1

Awards of Performance Shares may be made to certain Participants as an incentive for the performance of future services that will contribute materially to the successful operation of the Company. Awards of Performance Shares may be made either alone, in addition to or in tandem with other Awards granted under the Plan and/or cash payments made outside of the Plan.

11.2

With respect to Awards of Performance Shares, which may be issued for no consideration or such minimum consideration as is required by applicable law, the Committee shall:

(a)

determine and designate from time to time those Participants to whom Awards of Performance Shares are to be made;

(b)

determine the performance period (the “Performance Period”) and/or performance objectives (the “Performance Objectives”) applicable to such Awards;

(c)

determine the form of settlement of a Performance Share; and

(d)

generally determine the terms and conditions of each such Award. At any date, each Performance Share shall have a value equal to the Fair Market Value, determined as set forth in Section 2.15.

11.3

Performance Periods may overlap, and Participants may participate simultaneously with respect to Performance Shares for which different Performance Periods are prescribed.

11.4

The Committee shall determine the Performance Objectives of Awards of Performance Shares. Performance Objectives may vary from Participant to Participant and between Awards and shall be based upon such performance criteria or combination of factors as the Committee may deem appropriate. Performance Objectives

19

shall include any one or more of the following performance criteria, either individually, alternatively or in any combination, applied to either the Company as a whole or to a business unit or Subsidiary, either individually, alternatively or in any combination, and measured either annually or cumulatively over a period of years, on an absolute basis or relative to a pre-established target, to previous years’ results or to a designated comparison group, in each case as specified by the Committee: (a) operating income; (b) earnings before interest, taxes, depreciation and amortization (“EBITDA”); (c) earnings; (d) cash flow; (e) market share; (f) sales or revenue; (g) expenses; (h) profit/loss or profit margin; (i) working capital; (j) return on equity or capital; (k) earnings per share; (l) stock price; (m) price/earnings ratio; (n) debt or debt-to-equity; (o) balance sheet measurements; (p) cash or assets; (q) liquidity; (r) economic value added (“EVA”); (s) operations; (t) mergers and acquisitions or divestitures; (y) development status of product candidates; and (z) status of clinical trials. If during the course of a Performance Period there shall occur significant events which the Committee expects to have a substantial effect on the applicable Performance Objectives during such period, the Committee may revise such Performance Objectives.

11.5

The Committee shall determine for each Participant the number of Performance Shares which shall be paid to the Participant if the applicable Performance Objectives are exceeded or met in whole or in part.

11.6

If a Participant terminates service with the Company during a Performance Period because of death, Disability, Retirement or under other circumstances in which the Committee in its discretion finds that a waiver would be appropriate, that Participant, as determined by the Committee, may be entitled to a payment of Performance Shares at the end of the Performance Period based upon the extent to which the Performance Objectives were satisfied at the end of such period and prorated for the portion of the Performance Period during which the Participant was employed by the Company; provided, however, the Committee may, in its sole discretion, provide for an earlier payment in settlement of such Performance Shares in such amount and under such terms and conditions as the Committee deems appropriate or desirable. If a Participant terminates service with the Company during a Performance Period for any other reason, then such Participant shall not be entitled to any payment with respect to that Performance Period unless the Committee shall otherwise determine.

11.7

Each Award of a Performance Share shall be paid in whole shares of Stock, or cash, or a combination of Stock and cash as the Committee shall determine, with payment to be made as soon as practicable after the end of the relevant Performance Period.

11.8

The Committee shall have the authority to approve requests by Participants to defer payment of Performance Shares on terms and conditions approved by the Committee and set forth in a written Award Agreement between the Participant and the Company entered into in advance of the time of receipt or constructive receipt of payment by the Participant.

ARTICLE XII

OTHER STOCK-BASED AWARDS

12.1

Other awards of Stock and other awards that are valued in whole or in part by reference to, or are otherwise based on, Stock (“Other Stock-Based Awards”), including, without limitation, convertible preferred stock, convertible debentures, exchangeable securities, phantom stock and Stock awards or options valued by reference to book value or performance, may be granted either alone or in addition to or in tandem with Stock Options, Stock Rights, Restricted Stock, Deferred Stock or Stock Awards granted under the Plan and/or cash awards made outside of the Plan. Subject to the provisions of the Plan, the Committee shall have authority to determine the Eligible

20

Participants to whom and the time or times at which such Awards shall be made, the number of shares of Stock subject to such Awards, and all other conditions of the Awards. The Committee also may provide for the grant of

shares of Stock upon the completion of a specified Performance Period. The provisions of Other Stock-Based Awards need not be the same with respect to each recipient.

12.2

Other Stock-Based Awards made pursuant to this Article XII shall be subject to the following terms and conditions:

(a)

Subject to the provisions of this Plan and the Award Agreement, shares of Stock subject to Awards made under this Article XII may not be sold, assigned, transferred, pledged or otherwise encumbered prior to the date on which the shares are issued, or, if later, the date on which any applicable restriction, performance or deferral period lapses.

(b)

Subject to the provisions of this Plan and the Award Agreement and unless otherwise determined by the Committee at the time of the Award, the recipient of an Award under this Article XII shall be entitled to receive, currently or on a deferred basis, interest or dividends or interest or dividend equivalents with respect to the number of shares covered by the Award, as determined at the time of the Award by the Committee, in its sole discretion, and the Committee may provide that such amounts (if any) shall be deemed to have been reinvested in additional Stock or otherwise reinvested.

(c)

Any Award under this Article XII and any Stock covered by any such Award shall vest or be forfeited to the extent so provided in the Award Agreement, as determined by the Committee, in its sole discretion.

(d)

Upon the Participant’s Retirement, Disability or death, or in cases of special circumstances, the Committee may, in its sole discretion, waive in whole or in part any or all of the remaining limitations imposed hereunder (if any) with respect to any or all of an Award under this Article XII.

(e)

Each Award under this Article XII shall be confirmed by, and subject to the terms of, an Award Agreement.

(f)

Stock (including securities convertible into Stock) issued on a bonus basis under this Article XII may be issued for no cash consideration.

(g)

Any such Award that is subject to Section 409A of the Code shall comply with the applicable deferral, distribution timing and other applicable rules under Section 409A (and any regulations thereunder).

12.3

Other Stock-Based Awards may include a phantom stock Award, which is subject to the following terms and conditions:

(a)

The Committee shall select the Eligible Participants who may receive phantom stock Awards. The Eligible Participant shall be awarded a phantom stock unit, which shall be the equivalent to a share of Stock.

21

(b)

Under an Award of phantom stock, payment shall be made on the dates or dates as specified by the Committee or as stated in the Award Agreement and phantom stock Awards may be settled in cash, Stock, or some combination thereof; provided, that if such Award is subject to Section 409A of the Code, it shall comply with the applicable deferral, distribution timing and other applicable rules under Section 409A (and any regulations thereunder).

(c)

The Committee shall determine such other terms and conditions of each Award as it deems necessary in its sole discretion.

ARTICLE XIII

ACCELERATION EVENTS

13.1

For the purposes of the Plan, an Acceleration Event shall occur in the event of a “Change in Control”.

13.2

A “Change in Control” shall be deemed to have occurred if:

(a)

Any “Person” as defined in Section 3(a)(9) of the Act, including a “group” (as that term is used in Sections 13(d)(3) and 14(d)(2) of the Act), but excluding the Company and any employee benefit plan sponsored or maintained by the Company and (including any trustee of such plan acting as trustee) who:

(i)

makes a tender or exchange offer for any shares of the Company’s Stock (as defined below) pursuant to which any shares of the Company’s Stock are purchased (an “Offer”); or

(ii)

together with its “affiliates” and “associates” (as those terms are defined in Rule 12b-2 under the Act) becomes the “Beneficial Owner” (within the meaning of Rule 13d-3 under the Act) of at least fifty percent (50%) of the Company’s Stock (an “Acquisition”);

(b)

The shareholders of the Company approve a definitive agreement or plan (i) to merge or consolidate the Company with or into another Company and (x) the Company shall not be the surviving corporation or (y) the Company shall be the surviving corporation and in connection therewith, all or part of the outstanding stock shall be changed into or exchanged for stock or other securities of any other Person or cash or any other property, (ii) to sell or otherwise dispose of 50% or more of its assets, or (iii) to liquidate the Company;

(c)

The Company shall be a party to a statutory share exchange with any other Person after which the Company is a subsidiary of any other Person; or

(d)

When, as a result of, or in connection with, any tender or exchange offer, merger or other business combination, sale of assets or contested election, or any combination of the foregoing, the individuals who, prior to such transaction, constitute the Board (the “Incumbent Directors”) cease for any reason other than death to constitute at least a majority thereof.

13.3

Upon the occurrence of an Acceleration Event, the Committee may, in its discretion, declare that all then outstanding Performance Shares with respect to which the applicable Performance Period has not been completed shall be paid as soon as practicable as follows:

22

(a)

all Performance Objectives applicable to the Award of Performance Shares shall be deemed to have been satisfied to the extent necessary to result in payment of one hundred percent (100%) of the Performance Shares covered by the Award; and

(b)

the applicable Performance Period shall be deemed to have ended on the date of the Acceleration Event;

(c)

the payment to the Participant shall be the amount determined either by the Committee, in its sole discretion, or in the manner stated in the Award Agreement. This amount shall then be multiplied by a fraction, the numerator of which is the number of full calendar months of the applicable Performance Period that have elapsed prior to the date of the Acceleration Event, and the denominator of which is the total number of months in the original Performance Period; and

(d)

upon the making of any such payment, the Award Agreement as to which it relates shall be deemed canceled and of no further force and effect.

13.4

Upon the occurrence of an Acceleration Event, the Committee, in its discretion, may declare that 50% of all then outstanding Stock Options not previously exercisable and vested as immediately exercisable and fully vested, in whole or in part. Notwithstanding the foregoing sentence, the percentage of outstanding Stock Options which may become immediately exercisable and fully vested upon the Acceleration Event may, in the Committee’s discretion, be higher or lower than 50%.

13.5

Upon the occurrence of an Acceleration Event, the Committee, in its discretion, may declare the restrictions applicable to Awards of Restricted Stock, Deferred Stock or Other Stock- Based Awards to have lapsed, in which case the Company shall remove all restrictive legends and stop-transfer orders applicable to the certificates for such shares of Stock, and deliver such certificates to the Participants in whose names they are registered.

13.6

The value of all outstanding Stock Option, Stock Rights, Restricted Stock, Deferred Stock, Performance Shares, Stock Awards and Other Stock-Based Awards, in each case to the extent vested, shall, unless otherwise determined by the Committee in its sole discretion at or after grant but prior to any Change in Control, be cashed out on the basis of the “Change in Control Price,” as defined in Section 13.7 as of the date such Change in Control is determined to have occurred or such other date as the Committee may determine prior to the Change in Control.

13.7

For purposes of Section 13.7, “Change in Control Price” means the highest price per share of Stock paid in any transaction reported on the Nasdaq Global Market tier of The Nasdaq Stock Market, or paid or offered in any bona fide transaction related to a Potential or actual Change in Control of the Company at any time during the sixty (60) day period immediately preceding the occurrence of the Change in Control, in each case as determined by the Committee except that, in the case of Incentive Stock Options and Stock Appreciation Rights (or Limited Stock Appreciation Rights) relating to such Incentive Stock Options, such price shall be based only on transactions reported for the date on which the Participant exercises such Stock Appreciation Rights (or Limited Stock Appreciation Rights). Notwithstanding the foregoing, Fair Market Value on the date of exercise shall be used for any Award, the use of any other value for which would result in the imposition of income taxes and penalties under Section 409A of the Code.

23

13.8

Notwithstanding the foregoing, the time for payment of any Award subject to Section 409A of the Code shall not be accelerated or otherwise changed under this Article to the extent such acceleration or other change would be contrary to the payment timing or other rules under Section 409A (or any regulations thereunder).

ARTICLE XIV

AMENDMENT AND TERMINATION

14.1

The Board, upon recommendation of the Committee, or otherwise, at any time and from time to time, may amend or terminate the Plan as may be necessary or desirable to implement or discontinue this Plan or any provision thereof. No amendment, without approval by the Company’s shareholders, shall:

(a)

alter the group of persons eligible to participate in the Plan;

(b)

extend the period during which Incentive Stock Option Awards may be granted beyond April 1, 2023;

(c)

limit or restrict the powers of the Board and the Committee with respect to the administration of this Plan; or

(d)

change any of the provisions of this Article XIV.

14.2

No amendment to or discontinuance of this Plan or any provision thereof by the Board or the shareholders of the Company shall, without the written consent of the Participant, adversely affect, as shall be determined by the Committee, any Award theretofore granted to such Participant under this Plan; provided, however, the Committee retains the right and power to:

(a)

annul any Award if the Participant competes against the Company or any Subsidiary or is terminated for cause as determined by the Committee;

(b)

provide for the forfeiture of shares of Stock or other gain under an Award as determined by the Committee for competing against the Company or any Subsidiary; and

(c)

convert any outstanding Incentive Stock Option to a Nonqualified Stock Option.

14.3

If an Acceleration Event has occurred, no amendment or termination shall impair the rights of any person with respect to an outstanding Award as provided in Article XIII.

ARTICLE XV

MISCELLANEOUS PROVISIONS

15.1

Nothing in the Plan or any Award granted hereunder shall confer upon any Participant any right to continue in the employ of the Company (or to serve as a director thereof) or interfere in any way with the right of the Company to terminate his or her employment at any time. Unless specifically provided otherwise, no Award granted under the Plan shall be deemed salary or compensation for the purpose of computing benefits under any employee

24

benefit plan or other arrangement of the Company or its Subsidiaries for the benefit of its employees unless the Company shall determine otherwise. No Participant shall have any claim to an Award until it is actually granted under the Plan. To the extent that any person acquires a right to receive payments from the Company under the Plan, such right shall, except as otherwise provided by the Committee, be no greater than the right of an unsecured general creditor of the Company. All payments to be made hereunder shall be paid from the general funds of the Company, and no special or separate fund shall be established and no segregation of assets shall be made to assure payment of such amounts, except as provided in Article VIII with respect to Restricted Stock and except as otherwise provided by the Committee.

15.2

The Company may make such provisions and take such steps as it may deem necessary or appropriate for the withholding of any taxes which the Company or any Subsidiary is required by any law or regulation of any governmental authority, whether federal, state or local, domestic or foreign, to withhold in connection with any Stock Option or the exercise thereof, any Stock Right or the exercise thereof, or in connection with any other type of equity- based compensation provided hereunder or the exercise thereof, including, but not limited to, the withholding of payment of all or any portion of such Award or (to the extent consistent with Section 409A of the Code) another Award under this Plan until the Participant reimburses the Company for the amount the Company is required to withhold with respect to such taxes, or canceling any portion of such Award or (to the extent consistent with Section 409A) another Award under this Plan in an amount sufficient to reimburse itself for the amount it is required to so withhold, or (to the extent consistent with Section 409A) selling any property contingently credited by the Company for the purpose of paying such Award or another Award under this Plan, in order to withhold or reimburse itself for the amount it is required to so withhold.

15.3

The Plan and the grant of Awards shall be subject to all applicable federal and state laws, rules, and regulations and to such approvals by any government or regulatory agency as may be required. Any provision herein relating to compliance with Rule 16b-3 under the Act shall not be applicable with respect to participation in the Plan by Participants who are not subject to Section 16(b) of the Act.

15.4

The terms of the Plan shall be binding upon the Company, its Subsidiaries, and their successors and assigns.

15.5

Neither a Stock Option, Stock Right, nor any other type of equity-based compensation provided for hereunder, shall be transferable except as provided for herein. If any Participant makes such a transfer in violation hereof, any obligation of the Company shall forthwith terminate.

15.6

This Plan and all actions taken hereunder shall be governed by the laws of the State of Florida, except to the extent preempted by ERISA.

15.7

The Plan is intended to constitute an “unfunded” plan for incentive and deferred compensation. With respect to any payments not yet made to a Participant by the Company, nothing contained herein shall give any such Participant any rights that are greater than those of a general creditor of the Company. In its sole discretion, the Committee may authorize the creation of trusts or other arrangements to meet the obligations created under the Plan to deliver shares of Stock or payments in lieu of or with respect to Awards hereunder; provided, however, that, unless the Committee otherwise determines with the consent of the affected Participant, the existence of such trusts or other arrangements is consistent with the “unfunded” status of the Plan.

25

15.8

Each Participant exercising an Award hereunder agrees to give the Committee prompt written notice of any election made by such Participant under Section 83(b) of the Code, or any similar provision thereof.

15.9

If any provision of this Plan or an Award Agreement is or becomes or is deemed invalid, illegal or unenforceable in any jurisdiction, or would disqualify the Plan or any Award Agreement under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Award Agreement, it shall be stricken and the remainder of the Plan or the Award Agreement shall remain in full force and effect.

15.10

All Awards shall, to extent applicable, comply and be administered in accordance with the rules and requirements of Section 409A of the Code. Notwithstanding any other provision of the Plan, the Committee may take such actions as it deems necessary or appropriate to ensure that any Award comply with or be exempt from Section 409A and may interpret this Plan in any manner necessary to ensure that Awards comply with or are exempt from Section 409A. In the event that the Committee determines that an Award should comply with or be exempt from Section 409A and that a Plan provision or Award Agreement provision is necessary to ensure that such Award complies with or is exempt from Section 409A of the Code, such provision shall be deemed included in the Plan or such Award Agreement. The Committee may also unilaterally reform any Agreement to the extent necessary to comply with Section 409A.

15.11

In the event that a Participant is a “specified employee” within the meaning of Section 409A (as determined by the Company or its delegate), any payment required under this Plan that is subject to Section 409A and is payable upon Termination of Employment, shall not be made or begin until the expiration of the 6-month period following the Participant’s Termination of Employment.

26

EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer and Principal Accounting Officer

I, Mike Tomas, certify that:

	1.	I have reviewed this report on Form 10-Q of Bioheart, Inc.;
	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
		a.	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
		b.	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
		c.	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
		d.	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
	5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
		a.	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
		b.	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 9, 2013					/s/Mike Tomas
				Name:	Mike Tomas
					President and Chief Executive Officer Chief Financial Officer and Principal Accounting Officer

EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Mike Tomas, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, Bioheart, Inc.’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2013 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: May 9, 2013		/s/Mike Tomas
	Name:	Mike Tomas
		President and Chief Executive Officer Chief Financial Officer and Principal Accounting Officer

EX-32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Mike Tomas, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, Bioheart, Inc.’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2013 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: May 9, 2013	By:	/s/ Mike Tomas
	Name:	Mike Tomas
		Chief Financial Officer & Principal Accounting Officer

XML

Stock Option and Warrants (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of options and activity
Options outstanding, Balance	7,817,852
Stock Options [Member]
Summary of options and activity
Options outstanding, Beginning Balance	7,853,376	4,636,318
Granted, Shares		3,300,000
Exercised, Shares
Forfeited/Expired, Shares	(35,524)	(82,942)
Options outstanding, Balance	7,817,852	7,853,376	4,636,318
Options Exercisable, Shares	3,681,284
Available for grant, Shares	0
Options outstanding, Weighted - Average Exercise Price, Beginning Balance	$ 0.67	$ 1.20
Granted, Weighted - Average Exercise Price		$ 0.04
Exercised, Weighted - Average Exercise Price
Forfeited/Expired, Weighted - Average Exercise Price	$ 5.67	$ 5.57
Options outstanding, Weighted - Average Exercise Price, Balance	$ 0.64	$ 0.67	$ 1.20
Options exercisable, Weighted - Average Exercise Price	$ 1.28
Options outstanding, Weighted - Average Remaining Contractual Term (in years)	8 years	8 years 2 months 12 days	8 years 1 month 6 days

XML

Subsequent Events (Details)	3 Months Ended	1 Months Ended		0 Months Ended
	Mar. 31, 2013	Apr. 30, 2013 Subsequent Event [Member]	Apr. 01, 2013 Subsequent Event [Member]	Apr. 25, 2013 Subsequent Event [Member] Forbearance Agreement [Member] Northstar Biotech Group, LLC [Member]	Apr. 17, 2013 Subsequent Event [Member] Forbearance Agreement [Member] Northstar Biotech Group, LLC [Member]
Subsequent Events (Textual)
Shares reserved for future issuance under 2013 Omnibus Plan			50,000,000
lease expiration extended date		Jul. 31, 2013
Common stock shares issued during period					10,000,000
Preferred stock shares issued during period				20,000,000
Description for remeasurement of exercise price of options granted in past three years	Exercise price of the average of the last 5 trading days' closing price as of February 25, 2013.

XML

Fair Value Measurement (Details) (USD $)	3 Months Ended		164 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
Summary of changes in fair value of the Company's Level 3 financial liabilities
Beginning Balance	$ 611,227
Total (gains) losses
Initial fair value of debt derivative at note issuance	292,328
Mark-to-market at March 31, 2013:	640,589
Transfers out of Level 3 upon increase in authorized shares	(474,954)
Balance	1,069,190		1,069,190
Net Gain for the period included in earnings relating to the liabilities held at March 31, 2013	$ (640,589)		$ (545,820)

XML

Standby Equity Distribution Agreement (Details) (USD $)	1 Months Ended
	Nov. 30, 2011
Standby Equity Distribution Agreement (Textual)
Funds contributed by Greystone	$ 1,000,000
Period for which funding is provided	24 months
Transaction description of agreement with affiliates	For each share of our common stock purchased under the Agreement, Greystone will pay eighty percent (80%) of the average of the lowest daily volume weighted average price for five consecutive trading days immediately preceding Advance Notice (the "Valuation Period") commencing the date an Advance Notice (the "Advance Notice") is delivered to Greystone in a manner provided by the Agreement.

XML

Stock Option and Warrants (Tables)

3 Months Ended

Mar. 31, 2013

Stock Option and Warrants and Stock Compensation Expense [Abstract]

Summary of options and activity

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)
Options outstanding at January 1, 2012		4,636,318		$	1.20		8.1
Granted		3,300,000		$	0.04
Exercised				$
Forfeited/Expired		(82,942	)	$	5.57
Options outstanding at December 31, 2012		7,853,376		$	0.67		8.2
Granted				$
Exercised
Forfeited/Expired		(35,524	)	$	5.67
Options outstanding at March 31, 2013		7,817,852		$	0.64		8.0
Options exercisable at March 31, 2013		3,681,284		$	1.28
Available for grant at March 31, 2013		0

Summary of options outstanding and exercisable for stock-based payment awards

	Options Outstanding							Options Exercisable
	Shares		Weighted- Average Remaining Contractual Term		Weighted- Average Exercise Price		Shares			Weighted- Average Exercise Price
$0.00 – $0.70		6,794,360		8.7	$	0.12			2,599,127		$	0.18
$0.71 – $1.28		324,471		5.1	$	0.77			392,136		$	0.76
$5.25 – $5.67		652,653		2.6	$	5.56			643,653		$	5.57
$7.69		39,572		3.4	$	7.69			39,572		$	7.69
$8.47		6,796		4.0	$	8.47			6,796		$	8.47
		7,817,852		8.0	$	0.64			3,681,284		$	1.28

Summary of warrants and activity

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)
Outstanding at January 1, 2012		32,610,075		$	0.86		3.8
Issued		42,396,432		$	0.018		5.78
Exercised		—		$	0.00
Forfeited		(933,185	)	$	0.69
Outstanding at December 31, 2012		74,073,322		$	0.37		4.5
Issued		23,421,250		$	0.018		3.74
Exercised		—		$
Expired		(1,675,614	)	$	0.73
Outstanding at March 31, 2013		95,818,958		$	0.28		4.2
Exercisable at March 31, 2013		70,853,258		$	0.21		4.2

Summary of warrants outstanding and exercisable

	Warrants Outstanding						Warrants Exercisable
	Shares		Weighted- Average Remaining Contractual Term		Weighted- Average Exercise Price		Shares		Weighted- Average Exercise Price
$0.01 – $0.50		89,044,402		4.0	$	0.04		65,623,152		$	0.04
$0.52 – $0.68		2,831,642		5.8	$	0.58		2,831,642		$	0.58
$0.70 – $1.62		1,096,632		5.2	$	0.73		1,096,632		$	0.73
$3.60 – $4.93		105,000		0.4	$	4.87		105,000		$	4.87
$5.67 – $7.69		2,741,282		9.5	$	7.52		1,196,832		$	7.31
		95,818,958		4.2	$	0.28		70,853,258		$	0.21

XML

Stock Option and Warrants (Details 3) (Warrant [Member], USD $)	3 Months Ended
	Mar. 31, 2013
Warrants outstanding and exercisable
Warrants Outstanding, Shares	95,818,958
Warrants Outstanding, Weighted-Average Remaining Contractual Term	4 years 2 months 12 days
Warrants Outstanding, Weighted- Average Exercise Price	$ 0.28
Warrants Exercisable, Shares	70,853,258
Warrants Exercisable, Weighted-Average Exercise Price	$ 0.21
0.01 - $0.50 [Member]
Warrants outstanding and exercisable
Range of Exercise Prices, Minimum	$ 0.01
Range of Exercise Prices, Maximum	$ 0.50
Warrants Outstanding, Shares	89,044,402
Warrants Outstanding, Weighted-Average Remaining Contractual Term	4 years
Warrants Outstanding, Weighted- Average Exercise Price	$ 0.04
Warrants Exercisable, Shares	65,623,152
Warrants Exercisable, Weighted-Average Exercise Price	$ 0.04
0.52 - $0.68 [Member]
Warrants outstanding and exercisable
Range of Exercise Prices, Minimum	$ 0.52
Range of Exercise Prices, Maximum	$ 0.68
Warrants Outstanding, Shares	2,831,642
Warrants Outstanding, Weighted-Average Remaining Contractual Term	5 years 9 months 18 days
Warrants Outstanding, Weighted- Average Exercise Price	$ 0.58
Warrants Exercisable, Shares	2,831,642
Warrants Exercisable, Weighted-Average Exercise Price	$ 0.58
0.70 - $1.62 [Member]
Warrants outstanding and exercisable
Range of Exercise Prices, Minimum	$ 0.70
Range of Exercise Prices, Maximum	$ 1.62
Warrants Outstanding, Shares	1,096,632
Warrants Outstanding, Weighted-Average Remaining Contractual Term	5 years 2 months 12 days
Warrants Outstanding, Weighted- Average Exercise Price	$ 0.73
Warrants Exercisable, Shares	1,096,632
Warrants Exercisable, Weighted-Average Exercise Price	$ 0.73
3.60 - $4.93 [Member]
Warrants outstanding and exercisable
Range of Exercise Prices, Minimum	$ 3.60
Range of Exercise Prices, Maximum	$ 4.93
Warrants Outstanding, Shares	105,000
Warrants Outstanding, Weighted-Average Remaining Contractual Term	4 months 24 days
Warrants Outstanding, Weighted- Average Exercise Price	$ 4.87
Warrants Exercisable, Shares	105,000
Warrants Exercisable, Weighted-Average Exercise Price	$ 4.87
5.67 - $7.69 [Member]
Warrants outstanding and exercisable
Range of Exercise Prices, Minimum	$ 5.67
Range of Exercise Prices, Maximum	$ 7.69
Warrants Outstanding, Shares	2,741,282
Warrants Outstanding, Weighted-Average Remaining Contractual Term	9 years 6 months
Warrants Outstanding, Weighted- Average Exercise Price	$ 7.52
Warrants Exercisable, Shares	1,196,832
Warrants Exercisable, Weighted-Average Exercise Price	$ 7.31

XML

Derivative Liabilities (Details) (USD $)	0 Months Ended	3 Months Ended	1 Months Ended	3 Months Ended		1 Months Ended	3 Months Ended	1 Months Ended
	Feb. 04, 2013 Excessive Committed Shares [Member]	Mar. 31, 2013 Excessive Committed Shares [Member]	Mar. 31, 2013 Reset Warrants [Member]	Mar. 31, 2013 Reset Warrants [Member]	Oct. 01, 2012 Reset Warrants [Member]	Mar. 31, 2013 Convertible Notes Payable [Member]	Mar. 31, 2013 Convertible Notes Payable [Member]	Mar. 31, 2013 Convertible Notes Payable [Member] Minimum [Member]	Mar. 31, 2013 Convertible Notes Payable [Member] Maximum [Member]
Derivative Liabilities (Textual)
Increase in common stock, shares, authorized	970,000,000
Fair value of derivative liability	$ 474,954		$ 566,806	$ 566,806		$ 1,069,190	$ 1,069,190
Fair value of embedded derivatives						502,384	502,384
Dividend yield	0.00%		0.00%			0.00%
Expected volatility	156.52%		168.90%			168.90%
Risk free rate	0.38%		1.87%					0.119%	0.17%
Expected Term	3 years 6 months		9 years 6 months					14 days	8 months
loss on change in derivative liabilities		$ 84,907		$ 345,627			$ 210,056
Warrants issued to purchase common stock					15,000,000
Exercise price of warrant					0.014
Warrants exercisable period					10 years
Fair value of common stock						$ 0.038

XML

Fair Value Measurement (Details Textual) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Fair Value Measurement (Textual)
Derivative instruments that were designated as hedges	$ 0	$ 0
Derivative liability	$ 1,069,190	$ 611,227

XML

Inventory

3 Months Ended

Mar. 31, 2013

Inventory [Abstract]

INVENTORY

NOTE 3 – INVENTORY

Inventory consists of raw materials. Costs of raw materials are determined using the FIFO method. Inventory is stated at the lower of costs or market (estimated net realizable value). During the quarter ended March 31, 2013, the Company recorded a reserve for obsolescence of the full balance of inventory.

XML

Stock Option and Warrants (Details Textual) (USD $) Share data in Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Apr. 01, 2013 Subsequent Event [Member]
Stock Options and Warrants (Textual)
Shares reserved for future issuance under 2013 Omnibus Plan			50
Fair value of the option vested	$ 19,632	$ 19,051
Number of warrants granted	23

XML

Going Concern Matters (Details) (USD $)	3 Months Ended		164 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
Going Concern Matters (Textual)
Net losses attributable to common shareholders	$ 518,893
Net cash used in operating activities	(546,378)	(84,383)	(73,510,456)
Working capital deficit	$ 13,000,000		$ 13,000,000

XML

Significant Accounting Policies (Details) (USD $)	3 Months Ended		164 Months Ended		3 Months Ended	12 Months Ended	3 Months Ended
	Mar. 31, 2013 Employees	Mar. 31, 2012	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2013 Accounts Receivable [Member] Customer Concentration Risk [Member] Customer	Dec. 31, 2012 Accounts Receivable [Member] Customer Concentration Risk [Member] Customer	Mar. 31, 2013 Sales Revenue Goods and Services Net [Member] Customer Concentration Risk [Member] Customer	Mar. 31, 2012 Sales Revenue Goods and Services Net [Member] Customer Concentration Risk [Member] Customer
Significant Accounting Policies (Textual)
Concentration Risk, Percentage					100.00%	96.00%
Number of customer accounted for accounts receivable					2	1
Revenue	$ 4,192	$ 40,485	$ 1,273,832				$ 4,192	$ 40,895
Number of customers accounted for revenue							2	2
Deficit accumulated during development stage	115,556,617		115,556,617	115,037,724
Number of fully diluted shares outstanding	222,688,816	124,077,413
Option outstanding to purchase common stock	7,817,852		7,817,852
Options vested	3,681,284		3,681,284
Number of full time employees	3
Number of part time employees	1
Research and development expense	163,974	96,729	64,857,026
Derivative instruments that were designated as hedges	$ 0		$ 0	$ 0

XML

Commiments and Contingencies (Details) (USD $)	Mar. 31, 2013
Summary of future minimum obligations under the agreement
2013	$ 157,500
2014	210,000
2015	210,000
Total	$ 577,500

XML

Property and Equipment (Details) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Property and equipment
Laboratory and medical equipment	$ 352,358	$ 352,358
Furniture, fixtures and equipment	130,916	130,916
Computer equipment	54,414	54,414
Leasehold improvements	362,046	362,046
Property and equipment, Gross	899,734	899,734
Less accumulated depreciation and amortization	(898,684)	(897,914)
Property and equipment, net	$ 1,050	$ 1,820

XML

Accrued Expenses (Details) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Accrued expenses
License and royalty fees	$ 1,898,453	$ 1,825,675
Amounts payable to the Guarantors of the Company's loan agreement with Bank of America and Seaside Bank, including fees and interest	1,314,795	1,284,705
Interest payable on notes payable	507,644	1,100,174
Vendor accruals and other	174,268	120,133
Employee commissions, compensation, etc.	925,809	1,033,330
Accrued expenses, Total	$ 4,820,969	$ 5,364,017

XML

Going Concern Matters

3 Months Ended

Mar. 31, 2013

Going Concern Matters [Abstract]

GOING CONCERN MATTERS

NOTE 2 – GOING CONCERN MATTERS

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed consolidated financial statements, during three months ended March 31, 2013, the Company incurred net losses attributable to common shareholders of $518,893 and used $546,378 in cash for operating activities. As of March 31, 2013, the Company   had a working capital deficit of approximately $13.0 million. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.

The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

XML

Accrued Expenses (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2013
Accrued Expenses (Textual)
Accrued interest	$ 598,125
Restricted Common Stock [Member]
Accrued Expenses (Textual)
Amount of debt exchanged for shares	$ 500,000
Shares issued in conversion of debt	1,000,000
Number of debt holder	1

XML

Stock Option and Warrants (Details 1) (Stock Options [Member], USD $)	3 Months Ended
	Mar. 31, 2013
Options outstanding and exercisable for stock-based payment awards
Options Outstanding, Shares	7,817,852
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years
Options Outstanding, Weighted- Average Exercise Price	$ 0.64
Options Exercisable, Shares	3,681,284
Options Exercisable, Weighted-Average Exercise Price	$ 1.28
$0.00 - $0.70 [Member]
Options outstanding and exercisable for stock-based payment awards
Range of Exercise Prices, Minimum	$ 0.00
Range of Exercise Prices, Maximum	$ 0.70
Options Outstanding, Shares	6,794,360
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 8 months 12 days
Options Outstanding, Weighted- Average Exercise Price	$ 0.12
Options Exercisable, Shares	2,599,127
Options Exercisable, Weighted-Average Exercise Price	$ 0.18
$0.71 - $1.28 [Member]
Options outstanding and exercisable for stock-based payment awards
Range of Exercise Prices, Minimum	$ 0.71
Range of Exercise Prices, Maximum	$ 1.28
Options Outstanding, Shares	324,471
Options Outstanding, Weighted-Average Remaining Contractual Term	5 years 1 month 6 days
Options Outstanding, Weighted- Average Exercise Price	$ 0.77
Options Exercisable, Shares	392,136
Options Exercisable, Weighted-Average Exercise Price	$ 0.76
$5.25 - $5.67 [Member]
Options outstanding and exercisable for stock-based payment awards
Range of Exercise Prices, Minimum	$ 5.25
Range of Exercise Prices, Maximum	$ 5.67
Options Outstanding, Shares	652,653
Options Outstanding, Weighted-Average Remaining Contractual Term	2 years 7 months 6 days
Options Outstanding, Weighted- Average Exercise Price	$ 5.56
Options Exercisable, Shares	643,653
Options Exercisable, Weighted-Average Exercise Price	$ 5.57
$7.69 [Member]
Options outstanding and exercisable for stock-based payment awards
Range of Exercise Prices	$ 7.69
Options Outstanding, Shares	39,572
Options Outstanding, Weighted-Average Remaining Contractual Term	3 years 4 months 24 days
Options Outstanding, Weighted- Average Exercise Price	$ 7.69
Options Exercisable, Shares	39,572
Options Exercisable, Weighted-Average Exercise Price	$ 7.69
$8.47 [Member]
Options outstanding and exercisable for stock-based payment awards
Range of Exercise Prices	$ 8.47
Options Outstanding, Shares	6,796
Options Outstanding, Weighted-Average Remaining Contractual Term	4 years
Options Outstanding, Weighted- Average Exercise Price	$ 8.47
Options Exercisable, Shares	6,796
Options Exercisable, Weighted-Average Exercise Price	$ 8.47

XML

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 239,033
Accounts receivable, net	1,704	1,342
Inventory		62,953
Prepaid and other	79,360	41,533
Total current assets	320,097	105,828
Property and equipment, net	1,050	1,820
Other assets	54,661	54,662
Total assets	375,808	162,310
Current liabilities:
Bank overdraft		89
Accounts payable	2,533,718	2,618,567
Accrued expenses	4,820,969	5,364,017
Advances, related party	1,047,992	867,492
Deposits	465,286	465,286
Subordinated debt, related party	1,500,000	1,500,000
Notes payable, related party	966,227	966,227
Notes payable, net of debt discount	1,989,810	2,364,972
Total current liabilities	13,324,002	14,146,650
Long term debt:
Derivative liability	1,069,190	611,227
Stockholders' deficit:
Preferred stock, par value $0.001; 20,000,000 and 5,000,000 shares authorized as of March 31, 2013 and December 31, 2012, respectively, -0- issued and outstanding as of March 31, 2013 and December 31, 2012
Common stock, par value $0.001; 950,000,000 and 195,000,000 shares authorized as of March 31, 2013 and December 31, 2012, respectively, 190,496,693 and 182,062,802 shares issued and outstanding as of March 31, 2013 and December 31, 2012, respectively	190,497	182,063
Additional paid in capital	100,948,736	100,260,094
Common stock subscription	400,000
Deficit accumulated during development stage	(115,556,617)	(115,037,724)
Total stockholders' deficit	(14,017,384)	(14,595,567)
Total liabilities and stockholders' deficit	$ 375,808	$ 162,310

XML

Commiments and Contingencies (Details Textual) (USD $)	1 Months Ended	3 Months Ended		12 Months Ended			152 Months Ended	164 Months Ended
	Jun. 30, 2000	Mar. 31, 2013 Employees	Mar. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Mar. 31, 2012	Mar. 31, 2013
Commitments and Contingencies (Textual)
Patent expiration period	2015
Payment made to acquire license	$ 55,000
Annual license fee payable	10,000
Royalties payable	2% to 4% of net sales of products that are covered by the patents.
Minimum royalty threshold				200,000	200,000	200,000
License and royalty fees		1,898,453		1,825,675				1,898,453
License expenses incurred		72,778	52,500				1,898,453	1,898,453
Accrued interest for past due commitment under license agreement		At 2% over the prime rate.
Accrued expenses		335,953						335,953
Number of persons with continuing right to rescission		2
Repurchase consideration for unexercised options		77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted.
Total rescission liability		$ 371,000						$ 371,000

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended		164 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (518,893)	$ (946,892)	$ (115,556,617)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	769	4,325	898,684
Bad debt expense			166,266
Discount on convertible debt	124,838	248,776	1,736,406
Loss on change in fair value of derivative liability	640,589		545,820
Net gain on settlement of debt and trade payables	(1,004,224)		(1,004,224)
Non cash payment of interest	123,578	21,169	394,688
Amortization of warrants issued in exchange for licenses and intellectual property			5,413,156
Amortization of warrants issued in connection with notes payable		50,761	5,437,604
Amortization of loan costs		927	1,228,717
Warrants issued in exchange for services			285,659
Warrants issued in exchange for forbearance agreement			430,213
Equity instruments issued in connection with R&D agreement			360,032
Equity instruments issued in connection with settlement agreement			3,381,629
Common stock issued in connection with accounts payable			756,816
Common stock issued in exchange for services		10,000	1,482,522
Common stock issued in connection with amounts due to guarantors of Bank of America loan			69,159
Common stock issued in exchange for distribution rights and intellectual property			99,997
Warrants issued in connection with accounts payable			7,758
Stock based compensation	19,632	19,051	9,970,634
(Increase) decrease in:
Receivables	(362)	3,495	(2,969)
Inventory	62,953	416	(1)
Prepaid and other current assets	(37,827)	(38,599)	(89,329)
Other assets	1		(28,854)
Increase (decrease) in:
Accounts payable	(12,509)	254,157	3,247,170
Accrued expenses	55,077	288,031	6,793,321
Deferred revenue			465,287
Net cash used in operating activities	(546,378)	(84,383)	(73,510,456)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisitions of property and equipment			(899,733)
Net cash used by investing activities			(899,733)
CASH FLOWS FROM FINANCING ACTIVITIES:
Bank overdraft	(89)
Proceeds from issuance of common stock, net	400,000	117,500	64,281,775
Proceeds from (payments for) initial public offering of common stock, net			1,447,829
Proceeds from subordinated related party note			3,000,000
Payment of note payable			(3,000,000)
Proceeds from notes payable, related party			505,000
Proceeds from related party advances	180,500		1,047,992
Proceeds from exercise of stock options			293,749
Proceeds from notes payable	205,000		11,825,750
Repayments of notes payable			(3,533,605)
Payment of loan costs			(1,219,268)
Net cash provided in financing activities	785,411	117,500	74,649,222
Net (decrease) increase in cash and cash equivalents	239,033	33,117	239,033
Cash and cash equivalents, beginning of period		36,828
Cash and cash equivalents, end of period	239,033	69,945	239,033
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	103,969	128,696	2,288,051
Income taxes paid
Non cash financing activities:
Common stock issued in settlement of notes payable	19,500	387,033	4,252,959
Common stock issued in settlement of accounts payable	$ 146,740		$ 160,740

XML

Notes Payable (Details Textual) (USD $)	3 Months Ended		164 Months Ended					1 Months Ended		3 Months Ended		3 Months Ended	1 Months Ended				0 Months Ended	3 Months Ended		3 Months Ended		3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2013 Seaside Bank note payable [Member]	Dec. 31, 2012 Seaside Bank note payable [Member]	Oct. 25, 2010 Seaside Bank note payable [Member]	Apr. 30, 2009 August 2008 Unsecured Promissory Note [Member]	Aug. 20, 2008 August 2008 Unsecured Promissory Note [Member]	Mar. 31, 2013 August 2008 Unsecured Promissory Note [Member]	Dec. 31, 2012 August 2008 Unsecured Promissory Note [Member]	Mar. 31, 2013 August 2008 Unsecured Promissory Note [Member] Restricted Common Stock [Member]	Mar. 31, 2013 Hunton & Williams notes payable [Member] Notes_Payable	Dec. 31, 2012 Hunton & Williams notes payable [Member]	Mar. 31, 2013 Hunton & Williams notes payable [Member] Note payable one [Member]	Mar. 31, 2013 Hunton & Williams notes payable [Member] Note payable two [Member]	Jan. 09, 2013 IBC Funds note payable [Member]	Mar. 31, 2013 IBC Funds note payable [Member]	Dec. 31, 2012 IBC Funds note payable [Member]	Mar. 31, 2013 Asher notes payable [Member]	Dec. 31, 2012 Asher notes payable [Member]	Mar. 31, 2013 Asher notes payable [Member] Maximum [Member]	Mar. 31, 2013 Asher notes payable [Member] Minimum [Member]
Notes Payable (Textual)
Net of unamortized debt discount	$ 80,162		$ 80,162
Notes payable	2,069,972		2,069,972	2,364,972	980,000	980,000	980,000			500,000	1,000,000		384,972	384,972			125,000	125,000		80,000
Common stock issued in connection with issuance of a note payable, Shares																	2,500,000
Effective interest rate	8.00%		8.00%	8.00%			4.25%
Notes payable, net of debt discount	1,989,810		1,989,810	2,364,972
Borrowings from third party pursuant to terms of unsecured promissory note and agreement									1,000,000
Interest rate bear by each unsecured convertible promissory notes									13.50%				8.00%				8.00%			8.00%
Debt instrument, Maturity date									May 31, 2010								Apr. 15, 2013
Gross proceeds from private placement									19,000,000
Occurrence period of repayment of loan									Within 12 months
Warrant issued to purchase common stock								451,053
Warrant exercise price								$ 0.5321
Fair value of warrant issued									195,694
Number of outstanding notes payable													2
Outstanding notes payable															61,150	323,822
Accrued interest	598,125
Shares issued in conversion of debt												1,000,000
Amount of debt exchanged for shares												500,000
Gain (loss) on settlement of note payable										1,078,625
Warrant expected term									10 years
Description of note payable																	The Note is convertible into common stock, at IBC's option, at a 60% discount to the average of the three lowest closing prices of the common stock during the 5 trading day period prior to conversion.			The Notes are convertible into common stock, at Asher's option, at a 42% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion.
Percentage of discount to the lowest closing price prior to conversion																	60.00%			42.00%
Fair value of embedded derivatives																	198,987			93,342
Debt repayment period																				All interest and principal must be repaid between September 11, 2013 and November 22, 2013
Amortization of debt discount	124,838	248,776	1,736,406															105,469		19,369
Interest expense																	$ 73,987			$ 13,342
Dividend yield																	0.00%			0.00%
Expected volatility																	155.34%					155.34%	154.80%
Risk free rate																	0.06%					0.17%	0.09%
Expected Term																	3 months 4 days					9 months	8 months 1 day
Estimated fair value of the Company's common stock																	$ 0.0135					$ 0.0373	$ 0.0151

XML

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2013

Property and Equipment [Abstract]

Property and equipment

	March 31, 2013			December 31, 2012
Laboratory and medical equipment	$	352,358		$	352,358
Furniture, fixtures and equipment		130,916			130,916
Computer equipment		54,414			54,414
Leasehold improvements		362,046			362,046
		899,734			899,734
Less accumulated depreciation and amortization		(898,684	)		(897,914	)
	$	1,050		$	1,820

XML

Related Party Transaction (Details) (USD $)			0 Months Ended	1 Months Ended					1 Months Ended
	Mar. 31, 2013	Dec. 31, 2012	Oct. 05, 2012 Northstar Biotechnology Group, LLC Promissory Note [Member]	Sep. 30, 2012 Northstar Biotechnology Group, LLC Promissory Note [Member]	Mar. 31, 2013 Northstar Biotechnology Group, LLC Promissory Note [Member]	Dec. 31, 2012 Northstar Biotechnology Group, LLC Promissory Note [Member]	Oct. 02, 2012 Northstar Biotechnology Group, LLC Promissory Note [Member]	Feb. 29, 2012 Northstar Biotechnology Group, LLC Promissory Note [Member]	Mar. 30, 2012 Promissory Note [Member]	Mar. 31, 2013 Officer and Director [Member]	Dec. 31, 2012 Officer and Director [Member]	Nov. 30, 2012 Officer and Director [Member]	Oct. 22, 2012 Officer and Director [Member]	Jun. 04, 2011 Officer and Director [Member]
Related Party Transactions (Textual)
Advances, related party	$ 1,047,992	$ 867,492
Outstanding principal amount of the Loan					601,227			544,267
Repayment terms									The first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012.
Warrant issued to purchase shares			15,000,000,000,000	5,000,000
Series A convertible preferred stock issued in exchange for payments						5,000,000	5,000,000
Common stock issued in exchange for payments							10,000,000
Value of debt outstanding							210,000
Percentage of revenues to be received as royalty			8.00%
Effective interest rate			12.85%
Subordinated debt, related party	1,500,000	1,500,000
Effective interest rate	8.00%	8.00%								8.00%	8.00%
Subordinated notes												$ 100,000	$ 125,000	$ 140,000

XML

Notes Payable (Tables)

3 Months Ended

Mar. 31, 2013

Notes Payable [Abstract]

Summary of notes payable

	March 31, 2013			December 31, 2012
Seaside Bank note payable.	$	980,000		$	980,000
August 2008 Unsecured Promissory Note		500,000			1,000,000
Hunton & Williams notes payable		384,972			384,972
IBC Funds note payable		125,000			—
Asher notes payable		80,000			—
Total notes payable		2,069,972			2,364,972
Less unamortized debt discount		(80,162	)		—
Total notes payable net of unamortized debt discount	$	1,989,810		$	2,364,972

XML

Significant Accounting Policies

3 Months Ended

Mar. 31, 2013

Significant Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES

A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed consolidated financial statements follows:

General

The accompanying unaudited condensed consolidated financial statements of Bioheart, Inc., (the “Company”), have been prepared in accordance with the rules and regulations (S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three month period ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ended December 31, 2013. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated December 31, 2012 financial statements and footnotes thereto included in the Company’s SEC Form 10-K.

Basis and business presentation

Bioheart, Inc (the “Company”) was incorporated under the laws of the State of Florida in August 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through March 31, 2013, the Company has accumulated a deficit through its development stage of $115,556,617.

The unaudited condensed consolidated financial statements include the accounts of the Company, and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Comprehensive Income

The Company does not have any items of comprehensive income in any of the periods presented.

Net Loss per Common Share, basic and diluted

The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options and warrants have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 222,688,816 and 124,077,413 for the three months ended March 31, 2013 and 2012, respectively.

Stock based compensation

The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values. (See note 10).

As of March 31, 2013, there were outstanding stock options to purchase 7,817,852 shares of common stock, 3,681,284 shares of which were vested.

Concentrations of Credit Risk

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. The financial stability of these institutions is periodically reviewed by senior management.

As of March 31, 2013 and December 31, 2012, two (2) and one (1) customer represented 100% and 96% of the Company’s accounts receivable, respectively.

For the three month periods ended March 31, 2013 and 2012, the Company's revenues earned from the sale of products and services were $4,192 and $40,895, from two (2) and two (2) customers, respectively.

Reliance on Key Personnel and Consultants

The Company has 3 full-time employees and 1  part-time employee. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.

Research and Development

The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $163,974 and $96,729 for the three months ended March 31, 2013 and 2012, respectively; and $64,857,026 from August 12, 1999 (date of inception) to March 31, 2013.

Fair Value

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.

Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2013 and December 31, 2012, the Company did not have any derivative instruments that were designated as hedges.

Recent Accounting Pronouncements

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed consolidated financial position, results of operations or cash flows.

XML

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Balance Sheets [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	950,000,000	195,000,000
Common stock, shares issued	190,496,693	182,062,802
Common stock, shares outstanding	190,496,693	182,062,802

XML

Stock Option and Warrants

3 Months Ended

Mar. 31, 2013

Stock Option and Warrants and Stock Compensation Expense [Abstract]

STOCK OPTIONS AND WARRANTS

NOTE 11 — STOCK OPTIONS AND WARRANTS

Stock Options

In December 1999, our Board of Directors and shareholders adopted our 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011.

In April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty million shares for issuance.

Effective April 1, 2013, the BOD resolved that stock options granted for the past three years as of February 25, 2013 be repriced for employees, management and board members, at the exercise price of the average of the last 5 trading days’ closing price as of February 25, 2013.

A summary of options at March 31, 2013 and activity during the year then ended is presented below:

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)
Options outstanding at January 1, 2012		4,636,318		$	1.20		8.1
Granted		3,300,000		$	0.04
Exercised				$
Forfeited/Expired		(82,942	)	$	5.57
Options outstanding at December 31, 2012		7,853,376		$	0.67		8.2
Granted				$
Exercised
Forfeited/Expired		(35,524	)	$	5.67
Options outstanding at March 31, 2013		7,817,852		$	0.64		8.0
Options exercisable at March 31, 2013		3,681,284		$	1.28
Available for grant at March 31, 2013		0

The following information applies to options outstanding and exercisable at March 31, 2013:

	Options Outstanding							Options Exercisable
	Shares		Weighted- Average Remaining Contractual Term		Weighted- Average Exercise Price		Shares			Weighted- Average Exercise Price
$0.00 – $0.70		6,794,360		8.7	$	0.12			2,599,127		$	0.18
$0.71 – $1.28		324,471		5.1	$	0.77			392,136		$	0.76
$5.25 – $5.67		652,653		2.6	$	5.56			643,653		$	5.57
$7.69		39,572		3.4	$	7.69			39,572		$	7.69
$8.47		6,796		4.0	$	8.47			6,796		$	8.47
		7,817,852		8.0	$	0.64			3,681,284		$	1.28

The fair value of all options vesting during the three months ended March 31, 2013 and 2012 of $19,632 and $19,051, respectively, was charged to current period operations.

Warrants

A summary of warrants at March 31, 2013 and activity during the year then ended is presented below:

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)
Outstanding at January 1, 2012		32,610,075		$	0.86		3.8
Issued		42,396,432		$	0.018		5.78
Exercised		—		$	0.00
Forfeited		(933,185	)	$	0.69
Outstanding at December 31, 2012		74,073,322		$	0.37		4.5
Issued		23,421,250		$	0.018		3.74
Exercised		—		$
Expired		(1,675,614	)	$	0.73
Outstanding at March 31, 2013		95,818,958		$	0.28		4.2
Exercisable at March 31, 2013		70,853,258		$	0.21		4.2

In conjunction with the authorized issuance of common stock, the Company granted approximately 23 million warrants during the quarter ended March 31, 2013.

The following information applies to warrants outstanding and exercisable at March 31, 2013:

	Warrants Outstanding						Warrants Exercisable
	Shares		Weighted- Average Remaining Contractual Term		Weighted- Average Exercise Price		Shares		Weighted- Average Exercise Price
$0.01 – $0.50		89,044,402		4.0	$	0.04		65,623,152		$	0.04
$0.52 – $0.68		2,831,642		5.8	$	0.58		2,831,642		$	0.58
$0.70 – $1.62		1,096,632		5.2	$	0.73		1,096,632		$	0.73
$3.60 – $4.93		105,000		0.4	$	4.87		105,000		$	4.87
$5.67 – $7.69		2,741,282		9.5	$	7.52		1,196,832		$	7.31
		95,818,958		4.2	$	0.28		70,853,258		$	0.21

XML

Document and Entity Information	3 Months Ended
	Mar. 31, 2013	Apr. 30, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	BIOHEART, INC.
Entity Central Index Key	0001388319
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Mar. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		200,623,903

XML

Commiments and Contingencies

3 Months Ended

Mar. 31, 2013

Commitments and Contingencies [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 12 — COMMITMENTS AND CONTINGENCIES

Royalty Payments

The Company is obligated to pay royalties on commercial sales of certain products that may be developed and sold under various licenses and agreements that have been obtained by the Company.

The Company has entered into various licensing agreements, which include the potential for royalty payments, as follows:

William Beaumont Hospital

In June 2000, the Company entered into an exclusive license agreement to use certain patents for the life of the patents in future projects. The patents expire in 2015. In addition to a payment of $55,000 the Company made to acquire the license, the Company is required to pay an annual license fee of $10,000 and royalties ranging from 2% to 4% of net sales of products that are covered by the patents. In order to maintain the exclusive license rights, the agreement also calls for a minimum annual royalty threshold. The minimum royalty threshold was $200,000 for 2011 and $200,000 for 2010. This minimum royalty threshold will remain $200,000 for 2012 and thereafter. As of March 31, 2013, the Company has not made any payments other than the initial payment to acquire the license. At March 31, 2013 and December 31, 2012, the Company’s liability under this agreement was $1,898,453 and $1,825,675, respectively, which is reflected as a component of accrued expenses on the consolidated balance sheets (see Note 5). During the three months ended March 31, 2013 and 2012, the Company incurred expenses of $72,778, $52,500, and $1,898,453 from August 12, 1999 (date of inception) to March 31, 2012. The Company has accrued interest for the past due commitment at 2% over the prime rate per the terms of the agreement. The Company has included $335,953 in accrued expenses as of March 31, 2013.

Approximate annual future minimum obligations under this agreement as of March 31, 2013 are as follows:

Year Ending December 31,
2013	$	157,500
2014		210,000
2015		210,000
Total	$	577,500

Contingency for Registration of the Company’s common stock

The Company believes that it may have issued options to purchase common stock to certain of its employees, directors and consultants in California in violation of the registration or qualification provisions of applicable California securities laws. As a result, the Company intends to make a rescission offer to these persons. The Company will make this offer to all persons who have a continuing right to rescission, which it believes to include two persons. In the rescission offer, in accordance with California law, the Company will offer to repurchase all unexercised options issued to these persons at 77% of the option exercise price multiplied by the number of option shares, plus interest at the rate of 7% from the date the options were granted. Based upon the number of options that were subject to rescission as of December 31, 2009, assuming that all such options are tendered in the rescission offer, the Company estimated that its total rescission liability would be up to approximately $371,000. However, as the Company believes there is only a remote likelihood the rescission offer will be accepted by any of these persons in an amount that would result in a material expenditure by the Company, no liability was recorded as of March 31, 2013 or December 31, 2012.

Litigation

The Company is subject to other legal proceedings that arise in the ordinary course of business. In the opinion of management, as of March 31, 2013, the amount of ultimate liability with respect to such matters, if any, in excess of applicable insurance coverage, is not likely to have a material impact on the Company’s business, financial position, consolidated results of operations or liquidity. However, as the outcome of litigation and other claims is difficult to predict significant changes in the estimated exposures could exist.

XML

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		164 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
Statements Of Operations [Abstract]
Revenue	$ 4,192	$ 40,485	$ 1,273,832
Cost of sales		417	551,904
Gross profit	4,192	40,068	721,928
Operating expenses:
Research and development	163,974	96,729	64,857,026
Marketing, general and administrative	370,533	468,099	37,208,369
Impairment of investment			58,695
Depreciation and amortization	769	4,325	898,683
Total operating expenses	535,276	569,153	103,022,773
Net loss from operations	(531,084)	(529,085)	(102,300,845)
Other income (expenses):
Development revenues			117,500
Net gain on settlement of debt and trade payables	1,004,224		1,004,224
Loss on change of fair value of derivative liability	(640,589)		(545,820)
Interest income			762,277
Other income	939	11,353	272,004
Interest expense	(352,383)	(429,160)	(14,865,957)
Total other income (expenses)	12,191	(417,807)	(13,255,772)
Net loss before income taxes	(518,893)	(946,892)	(115,556,617)
Income taxes (benefit)
NET LOSS	$ (518,893)	$ (946,892)	$ (115,556,617)
Net loss per common share, basic and diluted	$ (0.003)	$ (0.008)
Weighted average number of common shares outstanding, basic and diluted	185,421,093	114,974,051

XML

Standby Equity Distribution Agreement

3 Months Ended

Mar. 31, 2013

Standby Equity Distribution Agreement [Abstract]

STANDBY EQUITY DISTRIBUTION AGREEMENT

NOTE 6 – STANDBY EQUITY DISTRIBUTION AGREEMENT

On November 2, 2011, the Company and Greystone Capital Partners (“Greystone”) entered into a Standby Equity Distribution Agreement (the “Agreement”).  Pursuant to the Agreement, Greystone has agreed to provide the Company with up to $1,000,000 of funding for the 24-month period following the date a registration statement of the Company’s common stock is declared effective by the SEC (the “Equity Line”).  During this 24-month period, commencing on the date on which the SEC first declares effective our registration statement, the Company may request a draw down under the Equity Line by which the Company would sell shares of its common stock to Greystone, which is obligated to purchase the shares under the Agreement.  

For each share of our common stock purchased under the Agreement, Greystone will pay eighty percent (80%) of the average of the lowest daily volume weighted average price for five consecutive trading days immediately preceding Advance Notice (the "Valuation Period") commencing the date an Advance Notice (the "Advance Notice") is delivered to Greystone in a manner provided by the Agreement. Subject to certain limitations and floor price reductions, the Company may, at its sole discretion, issue a Put Notice to Greystone and Greystone will then be irrevocably bound to acquire such shares. The registration statement relating to the requested bond of the Company's common stock pursuant to the Agreement was declared effective on February 10, 2012.

XML

Accrued Expenses

3 Months Ended

Mar. 31, 2013

Accrued Expenses [Abstract]

ACCRUED EXPENSES

NOTE 5 – ACCRUED EXPENSES

Accrued expenses consisted of the following as of March 31, 2013 and December 31, 2012:

	March 31, 2013		December 31, 2012
License and royalty fees	$	1,898,453	$	1,825,675
Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest		1,314,795		1,284,705
Interest payable on notes payable		507,644		1,100,174
Vendor accruals and other		174,268		120,133
Employee commissions, compensation, etc.		925,809		1,033,330
	$	4,820,969	$	5,364,017

During the three months ended March 31, 2013, 1,000,000 shares of restricted common stock were issued to one debt holder  in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note.

XML

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2013

Accrued Expenses [Abstract]

Accrued expenses

	March 31, 2013		December 31, 2012
License and royalty fees	$	1,898,453	$	1,825,675
Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest		1,314,795		1,284,705
Interest payable on notes payable		507,644		1,100,174
Vendor accruals and other		174,268		120,133
Employee commissions, compensation, etc.		925,809		1,033,330
	$	4,820,969	$	5,364,017

XML

Fair Value Measurement

3 Months Ended

Mar. 31, 2013

Fair Value Measurement [Abstract]

FAIR VALUE MEASUREMENT

NOTE 13 — FAIR VALUE MEASUREMENT

The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the consolidated financial statements.

The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.

As of March 31, 2013 or December 31, 2012, the Company did not have any items that would be classified as level 1 or 2 disclosure.

The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in note 9 above. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

March 31, 2013 and December 31, 2012, the Company did not have any derivative instruments that were designated as hedges.

The derivative liability as of March 31, 2013, in the amount of $1,069,190 has a level 3 classification.

The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of March 31, 2013:

	Derivative Liability
Balance, December 31, 2012	$	611,227
Total (gains) losses
Initial fair value of debt derivative at note issuance		292,328
Mark-to-market at March 31, 2013:		640,589
Transfers out of Level 3 upon increase in authorized shares		(474,954	)
Balance, March 31, 2013	$	1,069,190
Net Gain for the period included in earnings relating to the liabilities held at March 31, 2013	$	(640,589	)

XML

Derivative Liabilities

3 Months Ended

Mar. 31, 2013

Derivative Liabilities [Abstract]

DERIVATIVE LIABILITIES

NOTE 9 — DERIVATIVE LIABILITIES

Excessive committed shares

On December 31, 2012, in connection with the previously issued stock options and warrants, the Company had the possibility of exceeding their common shares authorized when considering the number of possible shares that may be issuable to satisfy settlement provisions of these agreements after consideration of all existing instruments that could be settled in shares. The accounting treatment of derivative financial instruments required that the Company reclassify the derivative from equity to a liability at their fair values as of the date possible issuable shares exceeded the authorized level and at fair value as of each subsequent balance sheet date. Any change in fair value was recorded as non-operating, non-cash income or expense at each reporting date. If the fair value of the derivatives was higher at the subsequent balance sheet date, the Company recorded a non-operating, non-cash charge. If the fair value of the derivatives was lower at the subsequent balance sheet date, the Company recorded non-operating, non-cash income.

On February 4, 2013, in conjunction with the increase in authorized number of shares to 970,000,000, the Company determined it had adequate authorized shares to settle all of these agreements. As such, the Company adjusted the derivative liability to fair value on February 4, 2013 and reclassified the derivative liability to equity. The fair value of the derivative liability of $474,954 (a non-cash item) as of February 4, 2013 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 156.52%; risk free rate: 0.38%; and expected life: 3.5 years. The Company recorded a loss on change in derivative liabilities of $84,907 during the three months ended March 31, 2013.

Reset warrants

On October 1, 2012, in connection with the forbearance agreement with Northstar as discussed in Note 8 above, the Company issued an aggregate of 15,000,000 warrants to purchase the Company’s common stock with an exercise price of $0.014 per share for ten years with anti-dilutive (reset) provisions.

The Company has identified embedded derivatives related to the issued warrants. These embedded derivatives included certain and anti-dilutive (reset) provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to fair value as of each subsequent reporting date.

At March 31, 2013, the fair value of the reset provision of $566,806 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 168.90%; risk free rate: 1.87%; and expected life: 9.50 years. The Company recorded a loss on change in derivative liabilities of $345,627 during the three months ended March 31, 2013.

Convertible notes

During the three months ended March 31, 2013, the Company issued convertible notes (see Note 7 above).

These notes are convertible into common stock, at holders’ option, at a discount to the market price of the Company’s common stock. The Company has identified the embedded derivatives related to these notes. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Note and to fair value as of each subsequent reporting date.

The fair value of the embedded derivatives at March 31, 2013, in the amount of $502,384, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 168.90%, (3) weighted average risk-free interest rate of 0.119% to 0.17%, (4) expected lives of 0.04 to 0.65 years, and (5) estimated fair value of the Company’s common stock of $0.038 per share. The Company recorded a loss on change in derivative liabilities of $210,056 during the three months ended March 31, 2013.

Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

At March 31, 2013, the aggregate derivative liabilities was valued at $1,069,190, the Company believes an event under the contract that would create an obligation to settle in cash or other current assets is remote and has classified the obligation as a long term liability.

XML

Notes Payable

3 Months Ended

Mar. 31, 2013

Notes Payable [Abstract]

NOTES PAYABLE

NOTE 7 – NOTES PAYABLE

Notes payable were comprised of the following as of March 31, 2013 and December 31, 2012:

	March 31, 2013			December 31, 2012
Seaside Bank note payable.	$	980,000		$	980,000
August 2008 Unsecured Promissory Note		500,000			1,000,000
Hunton & Williams notes payable		384,972			384,972
IBC Funds note payable		125,000			—
Asher notes payable		80,000			—
Total notes payable		2,069,972			2,364,972
Less unamortized debt discount		(80,162	)		—
Total notes payable net of unamortized debt discount	$	1,989,810		$	2,364,972

Seaside Bank

On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by shareholders of the Company.

August 2008 Unsecured Promissory Note

On August 20, 2008, the Company borrowed $1.0 million from a third party pursuant to the terms of an unsecured Promissory Note and Agreement. Outstanding principal and interest on the loan, which accrues at the rate of 13.5% per annum, is payable in one balloon payment upon the Company’s repayment of the BlueCrest Loan, which is scheduled to mature in May 2010, however the Company is not obligated to make payments until BlueCrest Loan is paid off. In the event the Company completes a private placement of its common stock and/or securities exercisable for or convertible into its common stock which generates at least $19.0 million of gross proceeds, the Company may prepay, without penalty, all outstanding principal and interest due under the loan using the same type of securities issued in the subject private placement. Because repayment of the loan could occur within 12 months from the date of the balance sheet, the Company has classified this loan as short term. Subject to certain conditions, at the end of each calendar quarter during the time the loan is outstanding, the Company may, but is not required to, pay all or any portion of the interest accrued but unpaid as of such date with shares of its common stock. In April 2009, as consideration for the authorization to amend certain documents related to the Note, the Company issued to the Noteholder a warrant to purchase 451,053 shares of common stock at an exercise price of $0.5321 per share.

The warrant, which became exercisable immediately upon issuance, has a ten year term. This warrant had a fair value of $195,694, which was accounted for as additional paid in capital and reflected as a component of debt discount and is being amortized as interest expense ratably over the term of the loan.

During the three months ended March 31, 2013, 1,000,000 shares of restricted common stock were issued to the debt holder,  in exchange for $500,000 in principal and $598,125 of accrued interest relating to a previously issued note resulting in a gain of $1,078,625. A gain of $1,078,625 was included in the net gain on settlement of debt and trade payables on the statement of operations.

Hunton & Williams Notes

At March 31, 2013 and December 31, 2012, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822 are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.

IBC Funds, LLC Note

On January 9, 2013, the Company issued an unsecured promissory note and 2,500,000 shares of common stock with IBC Funds LLC. (“IBC”) in the principal amount of $125,000 (the “Note”).

The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on April 15, 2013. The Note is convertible into common stock, at IBC’s option, at a 60% discount to the average of the three lowest closing prices of the common stock during the 5 trading day period prior to conversion. The Company has identified the embedded derivatives related to the IBC Note. These embedded derivatives included certain conversion features provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of IBC Note and to fair value as of each subsequent reporting date. At the inception of the IBC Note, the Company determined the aggregate fair value of $198,987 of the embedded derivatives.

The fair value of the embedded derivatives was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 155.34%, (3) weighted average risk-free interest rate of 0.06%, (4) expected life of 0.26 year, and (5) estimated fair value of the Company’s common stock of $0.0135 per share. The initial fair value of the embedded debt derivative of $198,987 was allocated as a debt discount up to the proceeds of the note ($125,000) with the remainder ($73,987) charged to current period operations as interest expense. For three months ended March 31, 2013, the Company amortized $105,469 of debt discount to current period operations as interest expense.

Asher Notes (During this quarter)

During the three months ended March 31, 2013, the Company entered into a Securities Purchase Agreements with Asher Enterprises, Inc. (“Asher”), for the sale of an 8% convertible notes in aggregate principal amount of $80,000 (the “Note”).

The Notes bear interest at the rate of 8% per annum. All interest and principal must be repaid between September 11, 2013 and November 22, 2013. The Notes are convertible into common stock, at Asher’s option, at a 42% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Asher Notes. These embedded derivatives included certain conversion features and reset provision. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Asher Note and to fair value as of each subsequent reporting date. At the inception of the Asher Notes, the Company determined the aggregate fair value of $93,342 of the embedded derivatives.

The fair value of the embedded derivatives was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 154.80% to 155.34%, (3) weighted average risk-free interest rate of 0.09% to 0.17%, (4) expected lives of 0.67 to .75 years, and (5) estimated fair value of the Company’s common stock from $0.0151 to $0.0373 per share. The initial fair value of the embedded debt derivative of $93,342 was allocated as a debt discount up to the proceeds of the note ($80,000) with the remainder ($13,342) charged to current period operations as interest expense. For the three months ended March 31, 2013, the Company amortized $19,369 of debt discount to current period operations as interest expense.

XML

Related Party Transactions

3 Months Ended

Mar. 31, 2013

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

NOTE 8 — RELATED PARTY TRANSACTIONS

Lease Guarantee

The Company’s former Chairman of the Board, Chief Executive Officer and Chief Technology Officer has personally guaranteed the Company’s obligations under its lease for its facilities in Sunrise, Florida and has provided a personal guarantee for the Company credit card, which is for his own use only.

Advances

As of March 31, 2013 and December 31, 2012, the Company officers and directors have provided advances in the aggregate of $1,047,992 and $867,492 respectively, for working capital purposes. The advances are unsecured, due on demand and non-interest bearing.

Notes payable-related party

Northstar Biotechnology Group, LLC

On February 29, 2012, the Note issued to BlueCrest Master Fund Limited (as described above) was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267.

On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. As of September 30, 2012, the Company was in default, however, subsequent to September 30, 2012, the Company renegotiated the terms of the note, Northstar has agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in restricted stock.

On September 21, 2012, the company issued 5,000,000 warrants to Northstar that was treated as Additional interest expense upon issuance.

On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement whereby the Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights. As of March 31, 2013 the principle of this note was $601,227. In addition to the above consideration of preferred and common stock, the company issued 15,000,000 million warrants pursuant to the agreement.

In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.

Effective October 1, 2012, the effective interest rate will be 12.85% per annum.

In connection with the consideration paid, Northstar shall waive, from the effective date through the earlier of termination or expiration of the agreement, or satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued. In addition, the Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012).

Officer and Director Notes

At March 31, 2013 and December 31, 2012, the Company has outstanding notes payable to officers and directors with interest at 8% per annum due at maturity. The three subordinated notes, $125,000, $100,000 and $140,000 were previously due on October 22, 2012, November 30, 2012 and June 4, 2011 respectively, and are unsecured. The company is not obligated to make payment until Northstar loan is paid off.

Subordinated debt, related party

As of March 31, 2013 and December 31, 2012, the Company officers and directors have provided notes in aggregate of $1,500,000. The notes are at 8% per annum and are due upon payoff of the Northstar note payable described above.

XML

Stockholders' Equity

3 Months Ended

Mar. 31, 2013

Stockholders' Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 10 – STOCKHOLDERS’ EQUITY

Preferred stock

On August 17, 2012, the board of directors designated 5,000,000 shares of preferred stock as Series A Convertible Preferred Stock which was increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. Each share of preferred stock is convertible into equal number of common shares at the option of the holder; entitled to 10 votes on all matters presented to be voted by the holders of common stock; upon event of liquidation, entitled to amount equal to stated value plus any accrued and unpaid dividends or other fees before distribution to junior securities.

Common stock

On February 4, 2013, the Company amended its Articles of Incorporation to increase the number of authorized shares to 970,000,000, consisting of 20,000,000 $0.001 par value preferred stock and 950,000,000 $0.001 common stock.

During the three months ended March 31, 2013, the Company issued an aggregate of 4,933,891 share of its common stock for settlement of $72,339 of accounts payable. In connection with the settlement, the Company recorded a loss on settlement of debt of $74,401.

During the three months ended March 31, 2013, the Company issued 2,500,000 shares of its common stock in connection with the issuance of a note payable.

During the three months ended March 31, 2013, the Company issued 1,000,000 shares of its common stock in connection with the settlement of a note payable.

XML

Notes Payable (Details) (USD $)	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2013 Seaside Bank note payable [Member]	Dec. 31, 2012 Seaside Bank note payable [Member]	Oct. 25, 2010 Seaside Bank note payable [Member]	Mar. 31, 2013 August 2008 Unsecured Promissory Note [Member]	Dec. 31, 2012 August 2008 Unsecured Promissory Note [Member]	Mar. 31, 2013 Hunton & Williams notes payable [Member]	Dec. 31, 2012 Hunton & Williams notes payable [Member]	Mar. 31, 2013 IBC Funds note payable [Member]	Jan. 09, 2013 IBC Funds note payable [Member]	Dec. 31, 2012 IBC Funds note payable [Member]	Mar. 31, 2013 Asher notes payable [Member]	Dec. 31, 2012 Asher notes payable [Member]
Summary of notes payable
Total notes payable	$ 2,069,972	$ 2,364,972	$ 980,000	$ 980,000	$ 980,000	$ 500,000	$ 1,000,000	$ 384,972	$ 384,972	$ 125,000	$ 125,000		$ 80,000
Less unamortized debt discount	(80,162)
Total notes payable net of unamortized debt discount	$ 1,989,810	$ 2,364,972

XML

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2013

Significant Accounting Policies [Abstract]

Basis and business presentation

Basis and business presentation

Bioheart, Inc (the “Company”) was incorporated under the laws of the State of Florida in August 1999. The Company is in the development stage, as defined by Accounting Standards Codification subtopic 915-10, Development Stage Entities (“ASC 915-10”) and is the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. To date, the Company has not generated significant sales revenues, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise. For the period from inception through March 31, 2013, the Company has accumulated a deficit through its development stage of $115,556,617.

The unaudited condensed consolidated financial statements include the accounts of the Company, and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Comprehensive Income

Comprehensive Income

The Company does not have any items of comprehensive income in any of the periods presented.

Net Loss per Common Share, basic and diluted

Net Loss per Common Share, basic and diluted

The Company has adopted Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share information. Basic loss per share has been calculated based upon the weighted average number of common shares outstanding. Stock options and warrants have been excluded as common stock equivalents in the diluted loss per share because their effect is anti-dilutive on the computation. Fully diluted shares outstanding were 222,688,816 and 124,077,413 for the three months ended March 31, 2013 and 2012, respectively.

Stock based compensation

Stock based compensation

The Company follows Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”) which requires that all share-based payments to both employees and non-employees be recognized in the income statement based on their fair values. (See note 10).

As of March 31, 2013, there were outstanding stock options to purchase 7,817,852 shares of common stock, 3,681,284 shares of which were vested.

Concentrations of Credit Risk

Concentrations of Credit Risk

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. The financial stability of these institutions is periodically reviewed by senior management.

As of March 31, 2013 and December 31, 2012, two (2) and one (1) customer represented 100% and 96% of the Company’s accounts receivable, respectively.

For the three month periods ended March 31, 2013 and 2012, the Company's revenues earned from the sale of products and services were $4,192 and $40,895, from two (2) and two (2) customers, respectively.

Reliance on Key Personnel and Consultants

Reliance on Key Personnel and Consultants

The Company has 3 full-time employees and 1  part-time employee. The Company is heavily dependent on the continued active participation of these current executive officers, employees and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.

Research and Development

Research and Development

The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $163,974 and $96,729 for the three months ended March 31, 2013 and 2012, respectively; and $64,857,026 from August 12, 1999 (date of inception) to March 31, 2013.

Fair Value

Fair Value

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.

Derivative Instrument Liability

Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2013 and December 31, 2012, the Company did not have any derivative instruments that were designated as hedges.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed consolidated financial position, results of operations or cash flows.

XML

Commiments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2013

Commitments and Contingencies [Abstract]

Summary of future minimum obligations under the agreement

Year Ending December 31,
2013	$	157,500
2014		210,000
2015		210,000
Total	$	577,500

XML

Stock Option and Warrants (Details 2) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of warrants and activity
Options outstanding, Balance	7,817,852
Warrant [Member]
Summary of warrants and activity
Options outstanding, Beginning Balance	74,073,322	32,610,075
Options outstanding, Weighted - Average Exercise Price, Beginning Balance	$ 0.37	$ 0.86
Warrants outstanding, Weighted - Average Remaining Contractual Term (in years)	4 years 2 months 12 days	4 years 6 months	3 years 9 months 18 days
Shares, issued	23,421,250	42,396,432
Warrants, Weighted-Average Exercise Price	$ 0.018	$ 0.018
Warrants, Weighted Average Remaining Contractual Term (in years)	3 years 8 months 26 days	5 years 9 months 11 days
Exercised, Shares
Exercised, Weighted - Average Exercise Price		$ 0.00
Forfeited/Expired, Shares	(1,675,614)	(933,185)
Forfeited/Expired, Weighted - Average Exercise Price	$ 0.73	$ 0.69
Options outstanding, Balance	95,818,958	74,073,322	32,610,075
Options outstanding, Weighted - Average Exercise Price, Balance	$ 0.28	$ 0.37	$ 0.86
Options Exercisable, Shares	70,853,258
Options exercisable, Weighted - Average Exercise Price	$ 0.21
Warrants exercisable, Weighted - Average Remaining Contractual Term (in years)	4 years 2 months 12 days

XML

Consolidated Statement of Stockholders' Deficit (Unaudited) (USD $)	Total	Preferred stock	Common stock	Additional Paid in Capital	Common Stock Subscribed	Deficit Accumulated During Development Stage
Beginning Balance at Dec. 31, 2012	$ (14,595,567)		$ 182,063	$ 100,260,094		$ (115,037,724)
Beginning Balance, Shares at Dec. 31, 2012			182,062,802
Reclassify the fair value of excess committed shares liability to equity upon common share authorization increase	474,954			474,954
Common stock issued in connection with issuance of convertible debt	36,250		2,500	33,750
Common stock issued in connection with issuance of convertible debt, Shares			2,500,000
Common stock issued in connection with settlement of debt	19,500		1,000	18,500
Common stock issued in connection with settlement of debt, Shares			1,000,000
Common stock issued in settlement of accounts payable	146,740		4,934	141,807
Common stock issued in settlement of accounts payable, Shares			4,933,891
Proceeds from common stock subscription	400,000				400,000
Stock based compensation	19,632			19,632
Net loss	(518,893)					(518,893)
Balance at Mar. 31, 2013	$ (14,017,384)		$ 190,497	$ 100,948,736	$ 400,000	$ (115,556,617)
Balance, Shares at Mar. 31, 2013			190,496,693

XML

Property and Equipment

3 Months Ended

Mar. 31, 2013

Property and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 4 – PROPERTY AND EQUIPMENT

Property and equipment as of March 31, 2013 and December 31, 2012 is summarized as follows:

	March 31, 2013			December 31, 2012
Laboratory and medical equipment	$	352,358		$	352,358
Furniture, fixtures and equipment		130,916			130,916
Computer equipment		54,414			54,414
Leasehold improvements		362,046			362,046
		899,734			899,734
Less accumulated depreciation and amortization		(898,684	)		(897,914	)
	$	1,050		$	1,820

Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives.

Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment.

XML

Fair Value Measurement (Tables)

3 Months Ended

Mar. 31, 2013

Fair Value Measurement [Abstract]

Summary of changes in fair value of the Company's Level 3 financial liabilities

	Derivative Liability
Balance, December 31, 2012	$	611,227
Total (gains) losses
Initial fair value of debt derivative at note issuance		292,328
Mark-to-market at March 31, 2013:		640,589
Transfers out of Level 3 upon increase in authorized shares		(474,954	)
Balance, March 31, 2013	$	1,069,190
Net Gain for the period included in earnings relating to the liabilities held at March 31, 2013	$	(640,589	)

XML

Stockholders' Equity (Details) (USD $)	3 Months Ended
	Mar. 31, 2013	Feb. 04, 2013	Dec. 31, 2012	Aug. 17, 2012 Votes
Stockholders Equity (Textual)
Number of votes hold by the holder per common share issued in conversion of preferred stock				10
Increased number of authorized capital, shares		970,000,000
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock issued in settlement of accounts payable	$ 146,740
Series A Convertible Preferred Stock [Member]
Stockholders Equity (Textual)
Preferred stock designated as Series A Convertible Preferred Stock				5,000,000
Preferred stock shares increased				20,000,000
Increased number of authorized capital, shares		20,000,000
Common stock [Member]
Stockholders Equity (Textual)
Increased number of authorized capital, shares		950,000,000
Common stock issued in settlement of accounts payable, Shares	4,933,891
Common stock issued in settlement of accounts payable	72,339
Loss on settlement of debt	$ 74,401
Common stock issued in connection with issuance of a note payable, Shares	2,500,000
Common stock issued in connection with settlement of note payable	1,000,000

XML

Subsequent Events

3 Months Ended

Mar. 31, 2013

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 14 — SUBSEQUENT EVENTS

As of April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty million shares for issuance.

Effective April 1, 2013, the BOD resolved that stock options granted for the past three years as of February 25, 2013 be repriced for employees, management and board members, at the exercise price of the average of the last 5 trading days’ closing price as of February 25, 2013.  

As of April, 2013, the Company amended its facility lease to extend the term of the lease until July 31, 2013.

As of April 17, 2013, in regards to the forbearance agreement, the Company issued 10,000,000 shares of its common stock to Northstar Biotech Group, LLC.

As of April 25, 2013, in regards to the forbearance agreement and in lieu of interest payments owed through April 1, 2013, the Company issued 20,000,000 shares of its preferred stock to Northstar Biotech Group, LLC.